{"gene":"MPO","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":1992,"finding":"X-ray crystal structure of canine myeloperoxidase at 3 Å resolution revealed a heterotetrameric enzyme (two heavy and two light chains linked by a disulfide bridge), with a covalently bound heme, proximal His336 ligand to heme iron, distal His95 and Arg239 as catalytic residues, a calcium binding site, and covalent linkage to heme tentatively at Glu242.","method":"X-ray crystallography (multiple isomorphous replacement, crystallographic refinement)","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure at 3 Å with refinement, foundational structural paper","pmids":["1320128"],"is_preprint":false},{"year":2000,"finding":"X-ray crystal structure of human MPO at 1.8 Å confirmed covalent heme attachment via two ester linkages (Glu242 and Asp94 to modified pyrrole methyl groups on rings A and C) and a sulfonium ion linkage (Met243 to vinyl group on pyrrole ring A). Halide-binding sites were characterized: a native chloride ion near the proximal His336 helix, and a bromide-binding site in the distal heme cavity near His95 that competes with H2O2 and may serve as the halide substrate-binding site in compound I.","method":"X-ray crystallography at 1.8 Å (native and bromide-soaked crystals)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional site characterization","pmids":["10766826"],"is_preprint":false},{"year":1997,"finding":"Kinetic studies established that thiocyanate is by far the most favored substrate for MPO over chloride and bromide (relative specificity constants Cl:Br:SCN = 1:60:730). At physiological concentrations of thiocyanate and chloride, MPO produces hypothiocyanite alongside HOCl, demonstrating thiocyanate as a major physiological substrate.","method":"In vitro enzyme kinetics (H2O2 consumption assay at varied substrate concentrations)","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — rigorous in vitro kinetic characterization with multiple substrate concentrations","pmids":["9359420"],"is_preprint":false},{"year":1998,"finding":"Stopped-flow transient kinetics revealed second-order rate constants for two-electron reduction of MPO compound I by halides and thiocyanate at pH 7: Cl⁻ (2.5×10⁴ M⁻¹s⁻¹), Br⁻ (1.1×10⁶ M⁻¹s⁻¹), I⁻ (7.2×10⁶ M⁻¹s⁻¹), SCN⁻ (9.6×10⁶ M⁻¹s⁻¹). A catalytic residue with pKa ~4.6 must be protonated for optimal halide oxidation. SCN⁻ most effectively shifts MPO from the peroxidatic to the halogenation cycle.","method":"Sequential mixing stopped-flow transient kinetics; steady-state spectral and kinetic measurements","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro transient kinetics with rigorous rate constant determinations","pmids":["9922160"],"is_preprint":false},{"year":2000,"finding":"MPO catalytically consumes nitric oxide (NO) as a substrate via its compound I and compound II intermediates in a H2O2-dependent manner, independent of chloride. Stopped-flow kinetics showed NO dramatically influences compound II steady-state levels, identifying peroxidases including MPO as a catalytic sink for NO at inflammation sites.","method":"Stopped-flow kinetics; steady-state NO consumption assay; in vitro enzyme assay with superoxide-generating system","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with stopped-flow kinetics demonstrating mechanistic interaction","pmids":["11090610"],"is_preprint":false},{"year":2000,"finding":"CD36 was identified as the major macrophage scavenger receptor for LDL modified by the MPO-H2O2-NO2⁻ system (NO2-LDL). MPO-dependent LDL modification generates a high-affinity CD36 ligand leading to foam cell formation; lipid oxidation products of phosphatidylcholine serve as the CD36-recognized moieties.","method":"Stable transfection of CD36; CD36-specific blocking mAbs; CD36-null macrophages; cholesterol loading and binding assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal approaches including KO cells, blocking antibodies, and receptor reconstitution","pmids":["10772654"],"is_preprint":false},{"year":2002,"finding":"MPO localizes in and around vascular endothelial cells following leukocyte degranulation during acute endotoxemia, where it catalytically consumes NO via substrate radicals, impairing endothelium-dependent relaxation. MPO-deficient mice were resistant to this vascular dysfunction, establishing MPO as a vascular NO oxidase modulating NO bioavailability during inflammation.","method":"Rodent model of acute endotoxemia; MPO-deficient mice; vascular relaxation assays; direct localization studies","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — genetic KO model with defined vascular functional phenotype plus localization data, replicated across conditions","pmids":["12089442"],"is_preprint":false},{"year":2002,"finding":"K⁺ flux into the neutrophil phagosome raises ionic strength and releases cationic granule proteins (elastase, cathepsin G) from anionic proteoglycan matrix; MPO-catalyzed halogenation contributes to the phagosomal oxidative environment. Mice deficient in granule proteases (but with intact superoxide/MPO activity) cannot resist staphylococcal/candidal infections, showing proteases are primary bactericidal effectors with MPO providing the oxidative context.","method":"Protease-deficient KO mice; infection models; ion flux measurements; morphological analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with defined infectious phenotype, mechanistic pathway placement","pmids":["11907569"],"is_preprint":false},{"year":2006,"finding":"Kinetic modeling of the neutrophil phagosome showed that MPO (present at millimolar concentrations) rapidly converts most superoxide to compound III, that superoxide is essential to recycle compound III and maintain MPO activity, and that MPO efficiently produces HOCl when chloride is adequate. Most HOCl reacts with granule proteins before reaching bacteria, and chloramine products may be the antimicrobial effectors.","method":"Kinetic mathematical modeling using known rate constants; estimated phagosomal concentrations","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 kinetic modeling — rigorous but computational without direct experimental validation in phagosome","pmids":["17074761"],"is_preprint":false},{"year":2010,"finding":"Upon neutrophil activation, neutrophil elastase (NE) escapes azurophilic granules and translocates to the nucleus where it degrades specific histones, promoting chromatin decondensation for NET formation. MPO then synergizes with NE to drive further chromatin decondensation independently of its enzymatic activity. NE-knockout mice fail to form NETs in a pulmonary Klebsiella pneumoniae model.","method":"NE-KO mice; pulmonary infection model; granule fractionation; nuclear translocation imaging; inhibitor studies; NET quantification","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with defined phenotype plus mechanistic fractionation and imaging, replicated with inhibitors","pmids":["20974816"],"is_preprint":false},{"year":2010,"finding":"Neutrophils from completely MPO-deficient donors fail to form NETs, establishing MPO as required for NET formation. Partial MPO deficiency allows NET formation; pharmacological MPO inhibition only delays/reduces NETs. MPO acts cell-autonomously (extracellular MPO products cannot rescue NET formation). NET-dependent killing of Candida albicans is compromised in MPO-deficient neutrophils.","method":"Neutrophils from MPO-deficient patients; pharmacological MPO inhibition; NET quantification; Candida killing assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — primary human genetic deficiency, pharmacological inhibition, and functional rescue experiments","pmids":["20974672"],"is_preprint":false},{"year":2010,"finding":"Human neutrophil MPO catalyzes biodegradation of single-walled carbon nanotubes via hypochlorite and reactive radical intermediates, both in vitro and in intact neutrophils. Molecular modeling indicated basic amino acids of MPO interact with carboxyls on nanotubes to position them near the catalytic site. Biodegraded nanotubes do not induce pulmonary inflammation in mice.","method":"In vitro MPO enzymatic assay; cell-based degradation in neutrophils and macrophages; molecular modeling; mouse aspiration model","journal":"Nature nanotechnology","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro enzymatic reconstitution, cell studies, molecular modeling, and in vivo validation","pmids":["20364135"],"is_preprint":false},{"year":2011,"finding":"MPO bound to NETs retains enzymatic peroxidase activity (~30% of total cellular MPO released with majority NET-bound). NET-associated MPO mediates H2O2-dependent killing of Staphylococcus aureus, demonstrating that MPO on NETs can contribute to extracellular antimicrobial activity.","method":"PMA-stimulated NET formation; peroxidase activity assay on NETs; MPO inhibitor; S. aureus killing assay with DNase-released NETs","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1–2 — direct enzyme activity measurement on NETs plus functional bacterial killing assay","pmids":["22131345"],"is_preprint":false},{"year":2012,"finding":"Requirements for NADPH oxidase and MPO in NET formation are stimulus-dependent: PMA and bacterial stimuli require NADPH oxidase; MPO is required for efficient PMA-induced NETs but dispensable for bacterium-induced NETs. Ionomycin (calcium ionophore) induces NETs independently of both NADPH oxidase and MPO.","method":"NADPH oxidase and MPO inhibitors; cells from MPO-deficient donor; multiple stimuli (PMA, bacteria, ionomycin); NET quantification","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — human genetic deficiency plus pharmacological inhibitors across multiple stimuli","pmids":["22802447"],"is_preprint":false},{"year":2014,"finding":"MPO forms a membrane-associated complex in azurophilic granules with NE that prevents NE release. ROS triggers MPO-dependent dissociation of NE from this complex into the cytosol and activates NE proteolytic activity. In the cytosol, NE binds and degrades F-actin to arrest actin dynamics before translocating to the nucleus during NETosis. This complex functions as an oxidative signaling scaffold.","method":"Biochemical fractionation; co-immunoprecipitation; actin dynamics assays; MPO inhibitors; NE activity assays; NET formation imaging","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal biochemical methods identifying complex, mechanism, and functional consequence","pmids":["25066128"],"is_preprint":false},{"year":2017,"finding":"Different NETosis stimuli engage distinct signaling pathways: PMA, C. albicans, and Group B Streptococcus use a PKC/ROS/MPO/NE-dependent pathway, whereas calcium ionophores (A23187, nigericin) require an alternative pathway independent of MPO and NADPH oxidase. All NET types are proteolytically active and kill bacteria.","method":"Pharmacological inhibitors (PKC, calcium, ROS, MPO, NE); neutrophils from chronic granulomatous disease and MPO-deficient patients; multiple stimuli; bacterial killing assay","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — human genetic deficiency models plus pharmacological dissection across multiple stimuli","pmids":["28574339"],"is_preprint":false},{"year":2004,"finding":"Enzymatically active MPO and its oxidation products (chlorotyrosine) are present in human brain neurons (hippocampal granule and pyramidal neurons) and activated microglia. MPO expression is increased in Alzheimer's disease brain tissue particularly in neurons and amyloid plaques. Several neuronal cell lines express MPO mRNA and protein, revealing unexpected neuronal expression of MPO.","method":"Immunohistochemistry; enzymatic activity assay; mass spectrometric detection of chlorotyrosine; RT-PCR; neuronal cell line analysis","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple methods (IHC, enzymatic activity, MS oxidation products, mRNA) in human tissue and cell lines","pmids":["15255951"],"is_preprint":false},{"year":1997,"finding":"Ceruloplasmin physically binds MPO and inhibits its peroxidase activity in a concentration-dependent manner. This interaction was demonstrated by MPO-affinity chromatography retaining ceruloplasmin from plasma, selective binding to MPO-coated plates (blockable by soluble MPO), and reciprocal binding of MPO to ceruloplasmin-coated plates (blockable by ceruloplasmin). C3 also binds MPO but does not inhibit its peroxidase activity.","method":"MPO-affinity chromatography; N-terminal amino acid sequencing; ELISA binding assays; peroxidase activity inhibition assay","journal":"Clinical and experimental immunology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding assays plus enzymatic inhibition with purified proteins","pmids":["9097926"],"is_preprint":false},{"year":2003,"finding":"Expression of MPO on the neutrophil surface is required for neutrophil activation by anti-MPO antibodies (ANCA). MPO-deficient neutrophils (completely and partially) showed no superoxide anion production in response to monoclonal anti-MPO or MPO-ANCA IgG, despite normal responses to other stimuli. Mutations causing deficiency were characterized at the molecular level.","method":"Neutrophils from MPO-deficient donors; superoxide anion production assay; immunocytochemistry; immunoblotting; mutation sequencing","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — human genetic deficiency with functional activation assays and molecular characterization of mutations","pmids":["12773517"],"is_preprint":false},{"year":2018,"finding":"MPO activates µ-calpain (but not m-calpain) in endothelial cells through denitrosylation of the µ-calpain C-terminus domain. Activated µ-calpain upregulates PP2A expression, which dephosphorylates AMPK (Thr172) and eNOS (Ser1177), leading to increased VCAM-1 and leukocyte adhesion. µ-Calpain-deficient mice showed reduced leukocyte adhesion in response to MPO, placing calpain as a novel downstream signaling target in MPO-induced endothelial dysfunction.","method":"Endothelial cell stimulation with MPO; calpain isoform-specific assays; pharmacological calpain inhibition; PP2A/AMPK/eNOS phosphorylation western blots; µ-calpain-deficient mice; leukocyte adhesion assay","journal":"Hypertension","confidence":"High","confidence_rationale":"Tier 2 — genetic KO mice plus pharmacological inhibition with defined molecular pathway (denitrosylation → calpain → PP2A → AMPK/eNOS)","pmids":["29507101"],"is_preprint":false},{"year":2016,"finding":"T47D breast cancer cells stably transfected with MPO replicate all post-ER processing steps for mature MPO heterotetramer formation, including proteolytic pro-domain removal, heavy/light chain separation, and inter-molecular disulfide bond formation. MPO traffics to lysosomes. Cys319 (which forms the inter-molecular disulfide bond) is also required for events preceding disulfide bonding: its mutation alters glycosylation, catalytic activity, and blocks entry into the endocytic pathway where proteolytic processing occurs.","method":"Stable transfection of MPO into T47D cells; site-directed mutagenesis of Cys319; immunofluorescence microscopy; glycosylation analysis; catalytic activity assay; endocytic pathway analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis combined with biochemical processing assays and microscopy in a novel cell model","pmids":["26890638"],"is_preprint":false},{"year":1996,"finding":"The human MPO promoter contains seven discrete nuclear protein binding sites (DP1–DP7) within the proximal 600 bp of 5'-flanking DNA, identified by DNase I footprinting and gel shift analysis. These sites show tissue-specific and maturation-specific differences in nuclear protein binding. Mutation of DP7 stimulates MPO promoter activity, while mutation of any of DP1–DP6 reduces activity, establishing them as positive cis-regulatory elements.","method":"DNase I footprinting; gel shift assays; promoter-reporter transfection with site-directed mutations","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1–2 — functional mutagenesis combined with protein binding assays identifies specific cis-elements","pmids":["8683986"],"is_preprint":false},{"year":1994,"finding":"A myeloid-lineage-specific enhancer for the murine MPO gene was identified 3.2–3.4 kb upstream, marked by a DNase I hypersensitive site. A 301 bp fragment encompassing this site has strong enhancer activity in MPO-expressing myeloid cells (WEHI 3BD+) but is inactive in lymphoid cells, requiring the complete 301 bp fragment for maximal activity.","method":"DNase I hypersensitivity mapping; transient transfection reporter assay in myeloid vs. lymphoid cell lines","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — functional enhancer activity demonstrated in cell-type-specific manner with deletion analysis","pmids":["8182931"],"is_preprint":false},{"year":2002,"finding":"The human MPO gene is transcribed in vivo primarily from the P1 promoter (~bp +1), with two additional non-canonical transcription initiation sites at P2 (~bp -310) and P3 (~bp -920). Transcription from P1 produces full-length coding transcripts and shows the expected downregulation upon myeloid differentiation. P2 and P3 transcripts do not downregulate upon TPA-induced macrophage differentiation, are non-tissue-specific, frequently terminate prematurely, and do not contribute to physiologic MPO expression.","method":"Primer extension; RT-PCR; Northern blot analysis of myeloid cell lines before and after differentiation induction","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — multiple primer extension and RT-PCR experiments with differentiation induction defining promoter usage in vivo","pmids":["12040446"],"is_preprint":false},{"year":2022,"finding":"MPO inhibition with the suicide inhibitor AZM198 stabilizes pre-existing unstable atherosclerotic plaque in the Tandem Stenosis mouse model, increasing fibrous cap thickness indicative of plaque stabilization, without altering cellular content (Ly6B.2+ or CD68+ cells) or MPO protein levels. In vivo molecular MRI showed elevated arterial MPO activity precedes unstable plaque formation.","method":"Tandem Stenosis mouse model; pharmacological MPO inhibition (AZM198); in vivo molecular MRI of MPO activity; histological analysis","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 2 — in vivo pharmacological intervention with imaging-confirmed target engagement and defined structural phenotype","pmids":["36375379"],"is_preprint":false},{"year":2022,"finding":"A homozygous missense mutation c.1769G>T (p.Arg590Leu) in MPO abolishes heme binding (structural analysis) and completely eliminates myeloperoxidase enzymatic activity in vitro. The mutant protein is stably expressed in culture but shows markedly reduced expression in patient skin in vivo, and is associated with generalized pustular psoriasis (GPP). Reduced NETosis (sparse NET formation in pustules) was observed in patient skin.","method":"Structural analysis (in silico heme binding prediction); in vitro myeloperoxidase activity assay in cultured cells; immunohistochemistry (anti-MPO and anti-citrullinated histone H3)","journal":"The Journal of dermatology","confidence":"High","confidence_rationale":"Tier 1–2 — functional enzyme assay, structural prediction, and in vivo histology converging on complete loss-of-function","pmids":["36585391"],"is_preprint":false},{"year":2022,"finding":"MPO-oxidized LDLs (Mox-LDLs) drive macrophage foam cell formation and increase intracellular ROS, but also stimulate endothelial cells to produce resolvin D1 (RvD1), a specialized pro-resolving mediator that reduces neutrophil/monocyte recruitment and promotes efferocytosis. Mox-LDLs thus exert a dual effect on inflammation through MPO-dependent LDL oxidation.","method":"In vitro cell-based assays with Mox-LDLs and macrophages/endothelial cells; RvD1 measurement","journal":"Antioxidants","confidence":"Medium","confidence_rationale":"Tier 3 — cell-based assays with defined outcomes but no genetic validation or in vivo model reported in this review","pmids":["35624738"],"is_preprint":false},{"year":2022,"finding":"MPO inhibition with verdiperstat attenuates LPS-induced acute lung injury in rats via the MPO/µ-calpain/β-catenin signaling pathway: MPO inhibition reduces µ-calpain activation, decreases nuclear β-catenin translocation, and restores VE-cadherin and claudin-5 levels, strengthening endothelial barrier function.","method":"LPS-induced two-hit rat ALI model; verdiperstat (MPO inhibitor) treatment; western blotting of µ-calpain cleavage, β-catenin localization, VE-cadherin, claudin-5; in vitro HPMEC model","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibition in vivo and in vitro with defined molecular pathway readouts","pmids":["35461824"],"is_preprint":false}],"current_model":"MPO is a heme-containing heterotetrameric peroxidase stored in neutrophil azurophilic granules whose catalytic core (with proximal His336, distal His95/Arg239, and covalent heme linkages at Glu242, Asp94, and Met243) oxidizes halides and thiocyanate (preferred order SCN⁻ >> I⁻ > Br⁻ >> Cl⁻) to hypohalous acids using H2O2; it also catalytically consumes nitric oxide, modulating vascular NO bioavailability. During NETosis, MPO forms a membrane complex with neutrophil elastase in azurophilic granules; ROS triggers MPO-dependent dissociation and activation of elastase, which degrades F-actin and translocates to the nucleus to decondense chromatin, with MPO then synergizing non-enzymatically to complete chromatin decondensation, making MPO essential for PMA-induced (but not ionophore-induced) NET formation. MPO also activates µ-calpain in endothelial cells via denitrosylation, suppressing eNOS phosphorylation through PP2A to promote vascular inflammation, and MPO-oxidized LDL is recognized by scavenger receptor CD36 to drive foam cell formation; MPO expression is controlled by seven cis-regulatory elements in its proximal promoter and a myeloid-specific upstream enhancer, with transcription occurring primarily from the P1 promoter during early myeloid differentiation and being downregulated upon terminal differentiation."},"narrative":{"teleology":[{"year":1992,"claim":"Determination of the first MPO crystal structure revealed the heterotetrameric architecture, covalent heme attachment, and catalytic residues (proximal His336, distal His95/Arg239), establishing the structural framework for understanding halide oxidation.","evidence":"X-ray crystallography at 3 Å of canine MPO with multiple isomorphous replacement","pmids":["1320128"],"confidence":"High","gaps":["Covalent heme linkages only tentatively assigned at this resolution","Human MPO structure not yet determined","No halide-binding site directly visualized"]},{"year":1994,"claim":"Identification of a myeloid-specific upstream enhancer and proximal promoter elements established the transcriptional regulatory framework for lineage-restricted MPO expression.","evidence":"DNase I hypersensitivity mapping and reporter assays in myeloid vs. lymphoid cell lines; DNase I footprinting and site-directed mutagenesis of promoter elements","pmids":["8182931","8683986"],"confidence":"High","gaps":["Trans-acting factors binding DP1–DP7 elements not identified","Chromatin context in primary myeloid progenitors not assessed"]},{"year":1997,"claim":"Kinetic characterization revealed thiocyanate as MPO's most favored physiological substrate over chloride and bromide, reframing MPO as a hypothiocyanite-producing enzyme alongside its HOCl-generating role, while ceruloplasmin was identified as a physiological inhibitor of MPO activity.","evidence":"In vitro enzyme kinetics with varied substrate concentrations; MPO-affinity chromatography and reciprocal binding assays with purified ceruloplasmin","pmids":["9359420","9097926"],"confidence":"High","gaps":["In vivo relative contributions of HOSCN vs. HOCl not quantified","Structural basis of ceruloplasmin–MPO interaction unknown"]},{"year":1998,"claim":"Stopped-flow transient kinetics defined absolute rate constants for compound I reduction by each halide and SCN⁻, revealing a catalytic residue with pKa ~4.6 required for halide oxidation and establishing that SCN⁻ most effectively shifts MPO from the peroxidatic to the halogenation cycle.","evidence":"Sequential mixing stopped-flow spectroscopy with compound I/II intermediates","pmids":["9922160"],"confidence":"High","gaps":["Identity of the pKa ~4.6 residue not assigned","Phagosomal pH dynamics not integrated"]},{"year":2000,"claim":"High-resolution human MPO structure resolved the three covalent heme linkages (Glu242, Asp94 ester bonds; Met243 sulfonium) and identified the distal halide-binding site, while parallel work established MPO as a catalytic NO sink and showed MPO-oxidized LDL drives CD36-dependent foam cell formation.","evidence":"1.8 Å X-ray crystallography of native and bromide-soaked crystals; stopped-flow NO consumption kinetics; CD36-transfected cells, CD36-null macrophages, and blocking antibodies","pmids":["10766826","11090610","10772654"],"confidence":"High","gaps":["In vivo NO consumption kinetics at inflammatory sites not measured","Structural basis of MPO–LDL interaction unresolved","Compound I–halide ternary complex not crystallized"]},{"year":2002,"claim":"MPO-deficient mice demonstrated that MPO catalytically consumes NO in vivo to impair endothelium-dependent vasodilation during inflammation, while granule protease-deficient mice showed that neutrophil proteases (not MPO-derived oxidants alone) are the primary bactericidal effectors, and promoter studies defined P1 as the physiologically relevant transcription start site.","evidence":"MPO-KO and protease-KO mouse infection/vascular relaxation models; primer extension and RT-PCR in differentiating myeloid cells","pmids":["12089442","11907569","12040446"],"confidence":"High","gaps":["Relative contribution of HOCl vs. chloramines to microbial killing in vivo unresolved","Mechanism of MPO subendothelial transcytosis not determined"]},{"year":2003,"claim":"Surface-expressed MPO was shown to be required for anti-MPO ANCA-mediated neutrophil activation, linking MPO to ANCA-associated vasculitis pathogenesis.","evidence":"Superoxide production assays in neutrophils from MPO-deficient donors stimulated with anti-MPO antibodies","pmids":["12773517"],"confidence":"High","gaps":["Mechanism of MPO surface translocation not defined","Whether surface MPO retains enzymatic activity during ANCA engagement unknown"]},{"year":2010,"claim":"MPO was established as essential for PMA-induced NETosis through a non-enzymatic synergy with neutrophil elastase in chromatin decondensation, with NE requiring prior MPO-dependent release from azurophilic granules and nuclear translocation to degrade histones.","evidence":"NE-KO mice with pulmonary infection; neutrophils from completely MPO-deficient human donors; granule fractionation and nuclear translocation imaging; NET quantification and Candida killing assays","pmids":["20974816","20974672"],"confidence":"High","gaps":["Molecular basis of MPO's non-enzymatic chromatin decondensation activity unknown","Whether MPO directly binds chromatin or histones not tested"]},{"year":2014,"claim":"Discovery that MPO and NE form a membrane-associated complex in azurophilic granules that acts as a ROS-sensing scaffold resolved how oxidative signals trigger NE release: ROS dissociates NE from MPO, enabling NE to degrade F-actin and halt actin dynamics before nuclear translocation.","evidence":"Co-immunoprecipitation; biochemical fractionation; actin dynamics assays; MPO inhibitors; NE activity assays","pmids":["25066128"],"confidence":"High","gaps":["Stoichiometry and structural basis of the MPO–NE complex not determined","ROS species responsible for complex dissociation not identified"]},{"year":2016,"claim":"Reconstitution of MPO biosynthesis in a non-myeloid cell line demonstrated that Cys319 is required not only for the inter-molecular disulfide bond forming the heterotetramer but also for correct glycosylation and entry into the endocytic processing pathway.","evidence":"Stable transfection of MPO into T47D cells; Cys319 site-directed mutagenesis; glycosylation analysis and endocytic pathway microscopy","pmids":["26890638"],"confidence":"High","gaps":["Chaperones and proteases mediating pro-domain removal not identified","Structural basis of Cys319-dependent glycosylation control unclear"]},{"year":2017,"claim":"Systematic dissection of NETosis stimuli confirmed two distinct pathways: a PKC/ROS/MPO/NE-dependent pathway (PMA, Candida, Streptococcus) and an MPO/NADPH oxidase-independent calcium pathway (ionophores), clarifying the stimulus-dependent requirement for MPO.","evidence":"Pharmacological inhibitor panel plus neutrophils from CGD and MPO-deficient patients across multiple stimuli","pmids":["28574339"],"confidence":"High","gaps":["Calcium-dependent NETosis effectors downstream of ionophore not identified","Whether mixed pathways operate simultaneously in vivo unknown"]},{"year":2018,"claim":"MPO was shown to activate endothelial µ-calpain (but not m-calpain) through denitrosylation, establishing a signaling cascade (µ-calpain → PP2A → AMPK/eNOS dephosphorylation → VCAM-1 upregulation) that explains how MPO promotes vascular inflammation beyond oxidant generation.","evidence":"Endothelial cell stimulation; calpain isoform-specific assays; µ-calpain-deficient mice; phosphorylation western blots; leukocyte adhesion assay","pmids":["29507101"],"confidence":"High","gaps":["Direct denitrosylation of µ-calpain not demonstrated biochemically with purified proteins","Whether this pathway operates in human vasculature in vivo not confirmed"]},{"year":2022,"claim":"Multiple 2022 studies consolidated MPO's pathological roles: pharmacological MPO inhibition stabilized atherosclerotic plaque in vivo, a homozygous loss-of-function mutation (Arg590Leu) abolishing heme binding was linked to generalized pustular psoriasis with defective NETosis, and MPO inhibition attenuated acute lung injury via the µ-calpain/β-catenin pathway.","evidence":"Tandem Stenosis mouse model with AZM198 and molecular MRI; patient mutation analysis with structural prediction and in vitro activity assay; rat ALI model with verdiperstat and junction protein analysis","pmids":["36375379","36585391","35461824"],"confidence":"High","gaps":["Clinical efficacy of MPO inhibitors in human cardiovascular or pulmonary disease not demonstrated","Mechanistic link between MPO deficiency and pustular psoriasis pathogenesis beyond NETosis not explored","β-catenin signaling downstream of µ-calpain not fully characterized"]},{"year":null,"claim":"Key unresolved questions include the structural basis of the non-enzymatic MPO–chromatin interaction during NETosis, the identity of the ROS species dissociating the MPO–NE granule complex, the in vivo relative contributions of HOCl vs. HOSCN vs. chloramines to antimicrobial defense, and whether therapeutic MPO inhibition translates to clinical benefit in cardiovascular and inflammatory diseases.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of MPO bound to chromatin or NE exists","In vivo pharmacokinetics of MPO-generated oxidants within the phagosome remain modeled rather than measured","Clinical trials of MPO inhibitors in atherosclerosis or ANCA vasculitis are ongoing but lack definitive outcomes"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,2,3,4,8,11,12]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[14,19]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[7,14]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[20]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[6,12]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,9,10,13,14,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,6,24,25]}],"complexes":["MPO-NE azurophilic granule membrane complex"],"partners":["ELANE","CD36","CAPN1","CP"],"other_free_text":[]},"mechanistic_narrative":"Myeloperoxidase (MPO) is a heme-containing heterotetrameric peroxidase stored in neutrophil azurophilic granules that generates hypohalous acids (HOCl, HOBr, HOSCN) from halides and thiocyanate using H₂O₂, with thiocyanate as the kinetically preferred substrate (SCN⁻ >> I⁻ > Br⁻ >> Cl⁻), and also catalytically consumes nitric oxide to modulate vascular NO bioavailability [PMID:9359420, PMID:9922160, PMID:11090610, PMID:12089442]. During NETosis, MPO forms a granule-membrane complex with neutrophil elastase (NE); ROS-triggered dissociation releases and activates NE, which degrades F-actin and translocates to the nucleus to decondense chromatin, after which MPO synergizes non-enzymatically to complete chromatin decondensation—making MPO essential for PMA-induced but dispensable for ionophore-induced NET formation [PMID:20974816, PMID:20974672, PMID:25066128, PMID:28574339]. MPO also drives vascular inflammation by activating endothelial µ-calpain via denitrosylation, suppressing eNOS phosphorylation through PP2A, and by generating oxidized LDL species recognized by the scavenger receptor CD36 to promote foam cell formation and atherosclerotic plaque instability [PMID:29507101, PMID:10772654, PMID:36375379]. A homozygous loss-of-function MPO mutation (p.Arg590Leu) that abolishes heme binding is associated with generalized pustular psoriasis and defective NETosis [PMID:36585391]."},"prefetch_data":{"uniprot":{"accession":"P05164","full_name":"Myeloperoxidase","aliases":[],"length_aa":745,"mass_kda":83.9,"function":"Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity (PubMed:9922160). Mediates the proteolytic cleavage of alpha-1-microglobulin to form t-alpha-1-microglobulin, which potently inhibits oxidation of low-density lipoprotein particles and limits vascular damage (PubMed:25698971)","subcellular_location":"Lysosome","url":"https://www.uniprot.org/uniprotkb/P05164/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MPO","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MPO","total_profiled":1310},"omim":[{"mim_id":"621409","title":"AUTOINFLAMMATION AND AUTOIMMUNITY, SYSTEMIC, WITH IMMUNE DYSREGULATION 2; AIAISD2","url":"https://www.omim.org/entry/621409"},{"mim_id":"617475","title":"SPECIFIC GRANULE DEFICIENCY 2; SGD2","url":"https://www.omim.org/entry/617475"},{"mim_id":"616714","title":"HMG-BOX TRANSCRIPTION FACTOR 1; HBP1","url":"https://www.omim.org/entry/616714"},{"mim_id":"616012","title":"JAGUNAL HOMOLOG 1; JAGN1","url":"https://www.omim.org/entry/616012"},{"mim_id":"613226","title":"ZINC FINGER PROTEIN 296; ZNF296","url":"https://www.omim.org/entry/613226"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":3249.5}],"url":"https://www.proteinatlas.org/search/MPO"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P05164","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05164","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05164-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05164-F1-predicted_aligned_error_v6.png","plddt_mean":89.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MPO","jax_strain_url":"https://www.jax.org/strain/search?query=MPO"},"sequence":{"accession":"P05164","fasta_url":"https://rest.uniprot.org/uniprotkb/P05164.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05164/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05164"}},"corpus_meta":[{"pmid":"24179165","id":"PMC_24179165","title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN.","date":"2013","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/24179165","citation_count":277,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32508671","id":"PMC_32508671","title":"Targeting Myeloperoxidase (MPO) Mediated Oxidative Stress and Inflammation for Reducing Brain Ischemia Injury: Potential Application of Natural Compounds.","date":"2020","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32508671","citation_count":202,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14729580","id":"PMC_14729580","title":"Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk.","date":"2004","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/14729580","citation_count":165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19995403","id":"PMC_19995403","title":"Gingival crevicular fluid levels of MMP-8, MMP-9, TIMP-2, and MPO decrease after periodontal therapy.","date":"2009","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/19995403","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11774269","id":"PMC_11774269","title":"Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia.","date":"2002","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11774269","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9097926","id":"PMC_9097926","title":"Binding and inhibition of myeloperoxidase (MPO): a major function of ceruloplasmin?","date":"1997","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9097926","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22331023","id":"PMC_22331023","title":"The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder.","date":"2012","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22331023","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18501296","id":"PMC_18501296","title":"MPO-ANCA induces IL-17 production by activated neutrophils in vitro via classical complement pathway-dependent manner.","date":"2008","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/18501296","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27375623","id":"PMC_27375623","title":"Peptidylarginine Deiminase Inhibitor Suppresses Neutrophil Extracellular Trap Formation and MPO-ANCA Production.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27375623","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26026247","id":"PMC_26026247","title":"NADPH oxidase, MPO, NE, ERK1/2, p38 MAPK and Ca2+ influx are essential for Cryptosporidium parvum-induced NET formation.","date":"2015","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26026247","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16170238","id":"PMC_16170238","title":"NQO1, MPO, and the risk of lung cancer: a HuGE review.","date":"2005","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16170238","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8565308","id":"PMC_8565308","title":"T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis.","date":"1996","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8565308","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22723783","id":"PMC_22723783","title":"Fibrosis in Atrial Fibrillation - Role of Reactive Species and MPO.","date":"2012","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22723783","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33790907","id":"PMC_33790907","title":"Neutrophil Extracellular Traps: A Potential Therapeutic Target in MPO-ANCA Associated Vasculitis?","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33790907","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33916434","id":"PMC_33916434","title":"The Enzymatic and Non-Enzymatic Function of Myeloperoxidase (MPO) in Inflammatory Communication.","date":"2021","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33916434","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18848868","id":"PMC_18848868","title":"NQO1, MPO, CYP2E1, GSTT1 and GSTM1 polymorphisms and biological effects of benzene exposure--a literature review.","date":"2008","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/18848868","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20844472","id":"PMC_20844472","title":"Intrinsic renal cell and leukocyte-derived TLR4 aggravate experimental anti-MPO glomerulonephritis.","date":"2010","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/20844472","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16195240","id":"PMC_16195240","title":"CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung.","date":"2005","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/16195240","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33886636","id":"PMC_33886636","title":"ELISA detection of MPO-DNA complexes in human plasma is error-prone and yields limited information on neutrophil extracellular traps formed in vivo.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33886636","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10917466","id":"PMC_10917466","title":"Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction.","date":"2000","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/10917466","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12773517","id":"PMC_12773517","title":"Expression of myeloperoxidase (MPO) by neutrophils is necessary for their activation by anti-neutrophil cytoplasm autoantibodies (ANCA) against MPO.","date":"2003","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/12773517","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26149790","id":"PMC_26149790","title":"Intermediate monocytes in ANCA vasculitis: increased surface expression of ANCA autoantigens and IL-1β secretion in response to anti-MPO antibodies.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26149790","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35178161","id":"PMC_35178161","title":"MPO/HOCl Facilitates Apoptosis and Ferroptosis in the SOD1G93A Motor Neuron of Amyotrophic Lateral Sclerosis.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35178161","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22285381","id":"PMC_22285381","title":"Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women.","date":"2012","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22285381","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18340529","id":"PMC_18340529","title":"A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk.","date":"2008","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/18340529","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16252100","id":"PMC_16252100","title":"Childhood microscopic polyangiitis associated with MPO-ANCA.","date":"2005","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/16252100","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12111688","id":"PMC_12111688","title":"Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk.","date":"2002","source":"American journal of industrial medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12111688","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24683438","id":"PMC_24683438","title":"Anti-inflammatory effect of recreational exercise in TNBS-induced colitis in rats: role of NOS/HO/MPO system.","date":"2014","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/24683438","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34379628","id":"PMC_34379628","title":"Circulating Myeloperoxidase (MPO)-DNA complexes as marker for Neutrophil Extracellular Traps (NETs) levels and the association with cardiovascular risk factors in the general population.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34379628","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23665205","id":"PMC_23665205","title":"Myeloperoxidase (MPO)-specific CD4+ T cells contribute to MPO-anti-neutrophil cytoplasmic antibody (ANCA) associated glomerulonephritis.","date":"2013","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23665205","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29507101","id":"PMC_29507101","title":"Mechanistic Role of the Calcium-Dependent Protease Calpain in the Endothelial Dysfunction Induced by MPO (Myeloperoxidase).","date":"2018","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/29507101","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32017001","id":"PMC_32017001","title":"Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32017001","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18558355","id":"PMC_18558355","title":"Natural and disease associated anti-myeloperoxidase (MPO) autoantibodies.","date":"2008","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18558355","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35632410","id":"PMC_35632410","title":"Dual-Positive MPO- and PR3-ANCA-Associated Vasculitis Following SARS-CoV-2 mRNA Booster Vaccination: A Case Report and Systematic Review.","date":"2022","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/35632410","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27906487","id":"PMC_27906487","title":"Neutrophil activation during acute human anaphylaxis: analysis of MPO and sCD62L.","date":"2017","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27906487","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27006681","id":"PMC_27006681","title":"Acute phase of aortic dissection: a pilot study on CD40L, MPO, and MMP-1, -2, 9 and TIMP-1 circulating levels in elderly patients.","date":"2016","source":"Immunity & ageing : I & A","url":"https://pubmed.ncbi.nlm.nih.gov/27006681","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15336400","id":"PMC_15336400","title":"Involvement of the mpo operon in resistance to class IIa bacteriocins in Listeria monocytogenes.","date":"2004","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/15336400","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31383567","id":"PMC_31383567","title":"Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis.","date":"2019","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/31383567","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30626536","id":"PMC_30626536","title":"Salivary levels of MPO, MMP-8 and TIMP-1 are associated with gingival inflammation response patterns during experimental gingivitis.","date":"2019","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/30626536","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20663217","id":"PMC_20663217","title":"Genetic Polymorphisms of CYP2E1, GSTP1, NQO1 and MPO and the Risk of Nasopharyngeal Carcinoma in a Han Chinese Population of Southern China.","date":"2010","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/20663217","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29383971","id":"PMC_29383971","title":"Evaluation of the oxidative stress-related genes ALOX5, ALOX5AP, GPX1, GPX3 and MPO for contribution to the risk of type 2 diabetes mellitus in the Han Chinese population.","date":"2018","source":"Diabetes & vascular disease research","url":"https://pubmed.ncbi.nlm.nih.gov/29383971","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28858733","id":"PMC_28858733","title":"Quercetin attenuates the ischemia reperfusion induced COX-2 and MPO expression in the small intestine mucosa.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28858733","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23224024","id":"PMC_23224024","title":"Possible implication of disordered neutrophil extracellular traps in the pathogenesis of MPO-ANCA-associated vasculitis.","date":"2012","source":"Clinical and experimental nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/23224024","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26576922","id":"PMC_26576922","title":"Systemic and coronary levels of CRP, MPO, sCD40L and PlGF in patients with coronary artery disease.","date":"2015","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/26576922","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31424363","id":"PMC_31424363","title":"Neutrophils as Sentinel Cells of the Immune System: A Role of the MPO-halide-system in Innate and Adaptive Immunity.","date":"2020","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31424363","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17483704","id":"PMC_17483704","title":"TNF-alpha, TNF-beta, IL-6, IL-10, PECAM-1 and the MPO inflammatory gene polymorphisms in osteosarcoma.","date":"2007","source":"Journal of pediatric hematology/oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17483704","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11434421","id":"PMC_11434421","title":"Possible risk reduction in esophageal cancer associated with MPO -463 A allele.","date":"2001","source":"Journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/11434421","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35624738","id":"PMC_35624738","title":"Unexpected Role of MPO-Oxidized LDLs in Atherosclerosis: In between Inflammation and Its Resolution.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35624738","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29166937","id":"PMC_29166937","title":"A putative Chondroprotective role for IL-1β and MPO in herbal treatment of experimental osteoarthritis.","date":"2017","source":"BMC complementary and alternative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29166937","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35833130","id":"PMC_35833130","title":"Clinical Significance of MPO-ANCA in Eosinophilic Granulomatosis With Polyangiitis: Experience From a Longitudinal Chinese Cohort.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35833130","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35774788","id":"PMC_35774788","title":"NETosis in Psoriatic Arthritis: Serum MPO-DNA Complex Level Correlates With Its Disease Activity.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35774788","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27616759","id":"PMC_27616759","title":"IL-1β promotes tubulointerstitial injury in 
MPO-ANCA-associated glomerulonephritis
.","date":"2016","source":"Clinical nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/27616759","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34759920","id":"PMC_34759920","title":"Comparative Histological Subtyping of Immune Cell Infiltrates in MPO-ANCA and PR3-ANCA Glomerulonephritis.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34759920","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8683986","id":"PMC_8683986","title":"Cis-elements in the promoter region of the human myeloperoxidase (MPO) gene.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8683986","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36375379","id":"PMC_36375379","title":"Therapeutic inhibition of MPO stabilizes pre-existing high risk atherosclerotic plaque.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/36375379","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33864596","id":"PMC_33864596","title":"DNA Hypomethylation of the MPO Gene in Peripheral Blood Leukocytes Is Associated with Cerebral Stroke in the Acute Phase.","date":"2021","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/33864596","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29041000","id":"PMC_29041000","title":"Genetic Variations of Oxidative Stress Related Genes ALOX5, ALOX5AP and MPO Modulate Ischemic Stroke Susceptibility Through Main Effects and Epistatic Interactions in a Chinese Population.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29041000","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37079267","id":"PMC_37079267","title":"In Silico Study in MPO and Molecular Docking of the Synthetic Drynaran Analogues Against the Chronic Tinnitus: Modulation of the M1 Muscarinic Acetylcholine Receptor.","date":"2023","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37079267","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2165203","id":"PMC_2165203","title":"Developmental and differential regulation of human MPO gene in leukemic cells.","date":"1990","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/2165203","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20418356","id":"PMC_20418356","title":"The MPO -463G>A polymorphism and cancer risk: a meta-analysis based on 43 case-control studies.","date":"2010","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20418356","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32052443","id":"PMC_32052443","title":"MMP9, CXCR1, TLR6, and MPO participant in the progression of coronary artery disease.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32052443","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34552111","id":"PMC_34552111","title":"Inflammatory signature in acute-on-chronic liver failure includes increased expression of granulocyte genes ELANE, MPO and CD177.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34552111","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12040446","id":"PMC_12040446","title":"Functional activity of three distinct myeloperoxidase (MPO) promoters in human myeloid cells.","date":"2002","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/12040446","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8182931","id":"PMC_8182931","title":"A myeloid-lineage-specific enhancer upstream of the mouse myeloperoxidase (MPO) gene.","date":"1994","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8182931","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2175239","id":"PMC_2175239","title":"Synovial fluid polymorphonuclear leucocytes from patients with rheumatoid arthritis have reduced MPO and NADPH-oxidase activity.","date":"1990","source":"British journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/2175239","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26059973","id":"PMC_26059973","title":"Neutrophil and monocyte responses to downhill running: Intracellular contents of MPO, IL-6, IL-10, pstat3, and SOCS3.","date":"2015","source":"Scandinavian journal of medicine & science in sports","url":"https://pubmed.ncbi.nlm.nih.gov/26059973","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34888651","id":"PMC_34888651","title":"Identification and functional characterization of a novel susceptibility locus for small vessel vasculitis with MPO-ANCA.","date":"2022","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34888651","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36585391","id":"PMC_36585391","title":"A homozygous loss-of-function variant in the MPO gene is associated with generalized pustular psoriasis.","date":"2022","source":"The Journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/36585391","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39457503","id":"PMC_39457503","title":"MPO-DNA Complexes and cf-DNA in Patients with Sepsis and Their Clinical Value.","date":"2024","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/39457503","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34839416","id":"PMC_34839416","title":"Patterns of lung diseases predict survival in patients with MPO-ANCA-associated vasculitis: a single-center retrospective study.","date":"2021","source":"Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/34839416","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34206992","id":"PMC_34206992","title":"New Insights on NETosis Induced by Entamoeba histolytica: Dependence on ROS from Amoebas and Extracellular MPO Activity.","date":"2021","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34206992","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34973310","id":"PMC_34973310","title":"Transcriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4+ Cytotoxic T Cells and an Involvement of the Complement System.","date":"2021","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/34973310","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19255975","id":"PMC_19255975","title":"Overexpression of ZNF342 by juxtaposition with MPO promoter/enhancer in the novel translocation t(17;19)(q23;q13.32) in pediatric acute myeloid leukemia and analysis of ZNF342 expression in leukemia.","date":"2009","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19255975","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30578659","id":"PMC_30578659","title":"Proteome Analyses Reveal Positive Association of COL2A1, MPO, TYMS, and IGFBP5 with Canine Mammary Gland Malignancy.","date":"2019","source":"Proteomics. Clinical applications","url":"https://pubmed.ncbi.nlm.nih.gov/30578659","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38837706","id":"PMC_38837706","title":"FTY720 ameliorates experimental MPO-ANCA-associated vasculitis by regulating fatty acid oxidation via the neutrophil PPARα-CPT1a pathway.","date":"2024","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38837706","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34611229","id":"PMC_34611229","title":"CircRNA_0079586 and circRNA_RanGAP1 are involved in the pathogenesis of intracranial aneurysms rupture by regulating the expression of MPO.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34611229","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36626226","id":"PMC_36626226","title":"PRTN3 variant correlates with increased autoantigen levels and relapse risk in PR3-ANCA versus MPO-ANCA disease.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36626226","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23840365","id":"PMC_23840365","title":"The MPO-463G>A polymorphism and lung cancer risk: a meta-analysis based on 22 case-control studies.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23840365","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32703233","id":"PMC_32703233","title":"An unusual presentation of propylthiouracil-induced anti-MPO and PR3 positive ANCA vasculitis with associated anti-GBM antibodies, IgA nephropathy and an IgG4 interstitial infiltrate: a case report.","date":"2020","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/32703233","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17140160","id":"PMC_17140160","title":"Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis.","date":"2006","source":"Clinical nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/17140160","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34890699","id":"PMC_34890699","title":"Hyperactive neutrophils infiltrate vital organs of tumor bearing host and contribute to gradual systemic deterioration via upregulated NE, MPO and MMP-9 activity.","date":"2021","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34890699","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1655065","id":"PMC_1655065","title":"Cytochemically unreactive neutrophils from subjects with myeloperoxidase (MPO) deficiency show a complex pattern of immunoreactivity with anti-MPO monoclonal antibodies: a flow cytometric and immunocytochemical study.","date":"1991","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/1655065","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25388618","id":"PMC_25388618","title":"Comparison of a novel chemiluminescence enzyme immunoassay (CLEIA) with enzyme-linked immunosorbent assay (ELISA) for the determination of MPO-ANCA in patients with ANCA-associated vasculitis.","date":"2014","source":"Modern rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/25388618","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28764808","id":"PMC_28764808","title":"Association between MPO-463G > A polymorphism and cancer risk: evidence from 60 case-control studies.","date":"2017","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28764808","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30543087","id":"PMC_30543087","title":"Expression changes of CD177 and MPO as novel biomarkers in lung tissue of CLP model rats.","date":"2018","source":"Turkish journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30543087","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35461824","id":"PMC_35461824","title":"Verdiperstat attenuates acute lung injury by modulating MPO/μ-calpain/β-catenin signaling.","date":"2022","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35461824","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36308438","id":"PMC_36308438","title":"Inhibitor of apoptosis proteins antagonist SM164 ameliorates experimental MPO-ANCA-associated vasculitis via enhancing fatty acid oxidation in neutrophils.","date":"2023","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36308438","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36088289","id":"PMC_36088289","title":"The potential pathogenic roles of S100A8/A9 and S100A12 in patients with MPO-ANCA-positive vasculitis.","date":"2022","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36088289","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26890638","id":"PMC_26890638","title":"T47D Cells Expressing Myeloperoxidase Are Able to Process, Traffic and Store the Mature Protein in Lysosomes: Studies in T47D Cells Reveal a Role for Cys319 in MPO Biosynthesis that Precedes Its Known Role in Inter-Molecular Disulfide Bond Formation.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26890638","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25764050","id":"PMC_25764050","title":"Therapeutic Potential of Ocimum tenuiflorum as MPO Inhibitor with Implications for Atherosclerosis Prevention.","date":"2015","source":"Journal of medicinal food","url":"https://pubmed.ncbi.nlm.nih.gov/25764050","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32847610","id":"PMC_32847610","title":"The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia.","date":"2020","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/32847610","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25120850","id":"PMC_25120850","title":"Immunohistochemical expression of MPO, CD163 and VEGF in inflammatory cells in acute respiratory distress syndrome: a case report.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25120850","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15031357","id":"PMC_15031357","title":"No association of G-463A myeloperoxidase gene polymorphism with MPO-ANCA-associated vasculitis.","date":"2004","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/15031357","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37981258","id":"PMC_37981258","title":"Circ-Plod2 destabilizes Mpo mRNA by binding to IGF2BP2 to promote osteogenic differentiation of bone marrow mesenchymal stem cells.","date":"2023","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37981258","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36439156","id":"PMC_36439156","title":"Implication of platelets and complement C3 as link between innate immunity and tubulointerstitial injury in renal vasculitis with MPO-ANCA seropositivity.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36439156","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29296208","id":"PMC_29296208","title":"The association of MPO gene promoter polymorphisms with Alzheimer's disease risk in Chinese Han population.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29296208","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25823564","id":"PMC_25823564","title":"Association of single nucleotide polymorphisms in MPO and COX genes with oral lichen planus.","date":"2015","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/25823564","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25056433","id":"PMC_25056433","title":"An association between MPO -463 G/A polymorphism and type 2 diabetes.","date":"2014","source":"Folia biologica","url":"https://pubmed.ncbi.nlm.nih.gov/25056433","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34549902","id":"PMC_34549902","title":"Polymorphisms in NQO1 and MPO genes and risk for bladder cancer in Tunisian population.","date":"2021","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34549902","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14556977","id":"PMC_14556977","title":"Prostanoids and MPO-halide system products as a link between innate and adaptive immunity.","date":"2003","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/14556977","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20974816","id":"PMC_20974816","title":"Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps.","date":"2010","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20974816","citation_count":1696,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11907569","id":"PMC_11907569","title":"Killing activity of neutrophils is mediated through activation of proteases by K+ flux.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11907569","citation_count":851,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12952835","id":"PMC_12952835","title":"Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.","date":"2003","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/12952835","citation_count":785,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28574339","id":"PMC_28574339","title":"Diverse stimuli engage different neutrophil extracellular trap pathways.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28574339","citation_count":640,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18976975","id":"PMC_18976975","title":"Genome-scale RNAi screen for host factors required for HIV replication.","date":"2008","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/18976975","citation_count":627,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20974672","id":"PMC_20974672","title":"Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20974672","citation_count":602,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25066128","id":"PMC_25066128","title":"A myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during NETosis.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25066128","citation_count":590,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12089442","id":"PMC_12089442","title":"Myeloperoxidase, a leukocyte-derived vascular NO oxidase.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12089442","citation_count":556,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23066164","id":"PMC_23066164","title":"Myeloperoxidase: a front-line defender against phagocytosed microorganisms.","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/23066164","citation_count":491,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20364135","id":"PMC_20364135","title":"Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation.","date":"2010","source":"Nature nanotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/20364135","citation_count":484,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17074761","id":"PMC_17074761","title":"Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17074761","citation_count":460,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24291281","id":"PMC_24291281","title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.","date":"2013","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/24291281","citation_count":431,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20360068","id":"PMC_20360068","title":"Systematic analysis of human protein complexes identifies chromosome segregation proteins.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20360068","citation_count":421,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10772654","id":"PMC_10772654","title":"Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species.","date":"2000","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10772654","citation_count":375,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22802447","id":"PMC_22802447","title":"Requirements for NADPH oxidase and myeloperoxidase in neutrophil extracellular trap formation differ depending on the stimulus.","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22802447","citation_count":353,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9359420","id":"PMC_9359420","title":"Thiocyanate and chloride as competing substrates for myeloperoxidase.","date":"1997","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9359420","citation_count":335,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11090610","id":"PMC_11090610","title":"Nitric oxide is a physiological substrate for mammalian peroxidases.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11090610","citation_count":332,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10766826","id":"PMC_10766826","title":"X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 A resolution.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10766826","citation_count":287,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22131345","id":"PMC_22131345","title":"Myeloperoxidase associated with neutrophil extracellular traps is active and mediates bacterial killing in the presence of hydrogen peroxide.","date":"2011","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22131345","citation_count":272,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15255951","id":"PMC_15255951","title":"Neuronal expression of myeloperoxidase is increased in Alzheimer's disease.","date":"2004","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15255951","citation_count":269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15714076","id":"PMC_15714076","title":"CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.","date":"2005","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15714076","citation_count":263,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1320128","id":"PMC_1320128","title":"X-ray crystal structure of canine myeloperoxidase at 3 A resolution.","date":"1992","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1320128","citation_count":253,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9922160","id":"PMC_9922160","title":"Reaction of myeloperoxidase compound I with chloride, bromide, iodide, and thiocyanate.","date":"1998","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9922160","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54639,"output_tokens":4364,"usd":0.114688},"stage2":{"model":"claude-opus-4-6","input_tokens":7875,"output_tokens":3397,"usd":0.18645},"total_usd":0.6757,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":68078,"output_tokens":7134,"usd":0.155622},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11132,"output_tokens":3612,"usd":0.21894}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Ceruloplasmin physically binds to MPO and inhibits its peroxidase activity in a concentration-dependent manner, as shown by affinity chromatography, reciprocal binding to coated microtitre plates, and competitive inhibition assays. C3 also binds MPO but does not inhibit peroxidase activity.\",\n      \"method\": \"Affinity chromatography, ELISA binding assay, N-terminal amino acid sequencing, immunochemistry, in vitro peroxidase inhibition assay\",\n      \"journal\": \"Clinical and experimental immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (affinity chromatography, reciprocal plate binding, competitive inhibition, sequencing) in a single study with rigorous controls\",\n      \"pmids\": [\"9097926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"A myeloid-lineage-specific enhancer located ~3.2–3.4 kb upstream of the mouse MPO gene drives expression specifically in granulocytic cells; a 301 bp fragment encompassing a DNase I hypersensitive site confers strong enhancer activity in MPO-expressing cells but not in lymphoid cells.\",\n      \"method\": \"DNase I hypersensitive site mapping, transient transfection reporter assay, sub-fragment analysis\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional dissection with reporter assays and DNase I mapping; strong experimental evidence for lineage-specific regulatory element\",\n      \"pmids\": [\"8182931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Seven discrete nuclear protein binding sites (DP1–DP7) were identified within the proximal 600 bp of the human MPO 5'-flanking region; mutation of DP7 stimulates MPO promoter activity while mutation of DP1–DP6 reduces it, indicating these cis-elements regulate MPO transcription with tissue- and maturation-specific differences in nuclear protein binding.\",\n      \"method\": \"DNase I footprinting, gel shift assay, site-directed mutagenesis, transfection reporter assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with footprinting and gel shift; multiple sites functionally validated\",\n      \"pmids\": [\"8683986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"MPO gene expression is developmentally and differentially regulated during myeloid differentiation: four MPO mRNA species (3.3, 3.1, 2.7, 2.5 kb) are expressed in HL-60 cells, with two species transiently upregulated at 1 h after differentiation induction and all four dramatically decreased at 10 h; MPO transcripts are detectable in M1–M4 AML but absent in M5 and CLL.\",\n      \"method\": \"Northern blot, primer extension, S1 nuclease protection assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal RNA analysis methods establishing regulated expression during differentiation\",\n      \"pmids\": [\"2165203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Human MPO gene transcription is initiated at three sites (~bp −920, −310, and +1, corresponding to promoters P3, P2, and P1); the P1 promoter drives the predominant large transcripts that are downregulated during myeloid differentiation, while P2 and P3 transcripts are non-tissue-specific, often terminate prematurely, and do not significantly contribute to physiologic MPO regulation.\",\n      \"method\": \"Primer extension, RT-PCR, Northern blot, transfection studies\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal molecular methods with in vivo and transfection validation\",\n      \"pmids\": [\"12040446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Expression of MPO on the neutrophil surface is required for activation of neutrophils by anti-MPO ANCA antibodies; MPO-deficient neutrophils (from donors with identified MPO gene mutations) failed to produce superoxide in response to anti-MPO monoclonal antibody or MPO-ANCA IgG despite normal responses to other stimuli.\",\n      \"method\": \"Functional assay using MPO-deficient donor neutrophils, superoxide production measurement, gene mutation identification by sequencing, immunocytochemistry, immunoblotting\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — natural loss-of-function model with multiple characterization methods and clear functional readout\",\n      \"pmids\": [\"12773517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MPO biosynthesis and trafficking require Cys319 for events preceding inter-molecular disulfide bond formation: mutation of Cys319 alters glycosylation, reduces catalytic activity, and blocks entry of proMPO into the endocytic pathway where proteolytic processing and disulfide bonding occur. Mature MPO traffics to lysosomal granules, and disulfide bond formation can occur independently of the proteolytic heavy/light chain separation.\",\n      \"method\": \"Stable transfection of T47D cells with MPO expression plasmid, site-directed mutagenesis (Cys319), immunofluorescence microscopy, lysosomal trafficking analysis, assessment of glycosylation and catalytic activity\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional and biochemical validation in a reconstituted cell model\",\n      \"pmids\": [\"26890638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MPO activates the μ-calpain isoform in endothelial cells via denitrosylation of μ-calpain's C-terminus; this leads to upregulation of PP2A, dephosphorylation of AMPK (Thr172) and eNOS (Ser1177), increased VCAM-1 expression, and enhanced leukocyte adhesion. Pharmacological calpain inhibition or genetic μ-calpain deficiency attenuates these MPO-induced effects.\",\n      \"method\": \"Endothelial cell stimulation with MPO, pharmacological inhibition, µ-calpain-deficient mouse model, VCAM-1 and adhesion assays, phosphorylation analysis\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including pharmacological inhibition, genetic KO, and in vitro/in vivo concordance\",\n      \"pmids\": [\"29507101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MPO inhibition with the suicide inhibitor AZM198 stabilizes pre-existing unstable atherosclerotic lesions in a mouse model: inhibiting arterial MPO activity increased fibrous cap thickness without affecting the cellular content of inflammatory cells or MPO protein, demonstrating that MPO enzymatic activity (not just protein presence) drives plaque instability.\",\n      \"method\": \"In vivo pharmacological MPO inhibition, molecular MRI of arterial MPO activity, histological analysis, interventional study design in Tandem Stenosis mouse model\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo interventional study with molecular imaging and histological validation demonstrating mechanism\",\n      \"pmids\": [\"36375379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A homozygous missense mutation (p.Arg590Leu) in MPO abolishes heme binding and completely eliminates myeloperoxidase enzymatic activity while permitting stable protein expression; in vivo the mutation causes protein instability and is associated with generalized pustular psoriasis, and MPO-deficient neutrophils in patient skin show sparse NET formation.\",\n      \"method\": \"Structural prediction of mutant MPO, in vitro activity assay in cultured cells, immunohistochemistry with anti-MPO and anti-citrullinated Histone H3 antibodies\",\n      \"journal\": \"The Journal of dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — loss-of-function mutation with in vitro functional assay, structural prediction, and in vivo phenotypic validation\",\n      \"pmids\": [\"36585391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MPO facilitates apoptosis and ferroptosis in SOD1G93A ALS motor neurons by activating the MPO/HOCl pathway: increased HOCl production increases the Bax/Bcl-2 ratio and caspase-3 (apoptosis) and inhibits GPX4 and NQO1 (ferroptosis/lipid peroxidation); MPO inhibition improves motor performance in SOD1G93A mice.\",\n      \"method\": \"HOCl fluorescent probe (HKOCl-3), SOD1G93A cell and mouse models, apoptosis and ferroptosis assays, MPO inhibition, rotarod behavioral test\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo with pharmacological inhibition, but mechanistic pathway placement based on single lab\",\n      \"pmids\": [\"35178161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Synovial fluid neutrophils from rheumatoid arthritis patients have degranulated and released ~26.5% of their MPO extracellularly prior to isolation (vs <2.9% in blood neutrophils), with reduced basal NADPH-oxidase activity but increased responsiveness to chemotactic peptide.\",\n      \"method\": \"MPO measurement by enzymatic assay, NADPH-oxidase activity measurement, cell viability assay, comparison of synovial vs blood PMN\",\n      \"journal\": \"British journal of rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct fractionation and functional measurement with clear phenotypic difference, single lab\",\n      \"pmids\": [\"2175239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In acute myeloid leukemia, a translocation t(17;19)(q22;q13.32) places ZNF342 under control of the MPO promoter/enhancer, resulting in significant ZNF342 overexpression; this demonstrates that the MPO promoter/enhancer region is functionally sufficient to drive ectopic gene expression in myeloid leukemia cells.\",\n      \"method\": \"FISH, vectorette PCR, breakpoint mapping, RNA expression analysis\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — molecular mapping of chromosomal breakpoint with functional expression consequence, single case but rigorous methods\",\n      \"pmids\": [\"19255975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Circ-Plod2 destabilizes Mpo mRNA by binding to IGF2BP2, forming an RNA-protein complex; overexpression of circ-Plod2 in bone marrow mesenchymal stem cells suppresses MPO expression and promotes osteogenic differentiation.\",\n      \"method\": \"RNA sequencing, luciferase assay, RNA-protein binding assay, siRNA/overexpression in BMSCs, in vivo OVX rat model\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway with binding assay and functional readout, single lab\",\n      \"pmids\": [\"37981258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-183-5p and miR-877-3p suppress expression of circRNA_0079586 and circRNA_RanGAP1, respectively, which in turn regulate MPO mRNA levels in endothelial cells; luciferase assays confirmed these regulatory relationships and MPO expression was positively correlated with circRNA levels and negatively with miRNA levels.\",\n      \"method\": \"Microarray, luciferase reporter assay, siRNA/overexpression, real-time PCR\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — luciferase validation of binding and correlation of expression, single lab, endothelial cell model\",\n      \"pmids\": [\"34611229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MPO-oxidized LDLs (Mox-LDLs) promote foam cell formation and induce production of resolvin D1 (RvD1) from endothelial cells, and drive macrophage polarization toward a mixed pro- and anti-inflammatory phenotype, implicating MPO-mediated LDL oxidation in both the promotion and resolution of inflammation in atherosclerosis.\",\n      \"method\": \"In vitro studies with Mox-LDL treatment of macrophages and endothelial cells, ROS measurement, polarization assays (reviewed mechanistic literature)\",\n      \"journal\": \"Antioxidants (Basel, Switzerland)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — review synthesizing in vitro mechanistic data, no primary experimental data in this paper\",\n      \"pmids\": [\"35624738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MPO activity is required for NET formation by human and bovine neutrophils in response to Cryptosporidium parvum sporozoites, as demonstrated by significant reduction of NETs with MPO inhibitors; NE and NADPH oxidase are also required.\",\n      \"method\": \"MPO inhibitor treatment, NET quantification by co-localization of extracellular DNA with MPO/histone/NE, parasite entrapment assay\",\n      \"journal\": \"Developmental and comparative immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition with functional readout, multiple inhibitors tested\",\n      \"pmids\": [\"26026247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Verdiperstat (MPO inhibitor) attenuates acute lung injury by inhibiting the MPO/µ-calpain/β-catenin signaling pathway: MPO inhibition reduces µ-calpain activation, decreases nuclear β-catenin, and restores VE-cadherin and claudin-5 in pulmonary endothelial cells.\",\n      \"method\": \"In vivo LPS two-hit rat ALI model, in vitro human pulmonary microvascular endothelial cells, Western blot for pathway proteins, pharmacological MPO inhibition\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro concordance with pharmacological inhibition and pathway protein measurement\",\n      \"pmids\": [\"35461824\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MPO is a heme-peroxidase stored in neutrophil/monocyte granules that catalyzes the production of hypochlorous acid (HOCl) from H₂O₂ and chloride; its transcription is driven by a primary P1 promoter and a myeloid-specific upstream enhancer regulated by multiple cis-elements (DP1–DP7), its proprotein undergoes multi-step endocytic processing requiring Cys319 for glycosylation, entry into the endocytic pathway, and ultimate formation of a disulfide-linked heterotetramer in lysosomes; surface-expressed MPO is required for ANCA-mediated neutrophil activation; secreted MPO activates endothelial µ-calpain via denitrosylation, leading to PP2A upregulation, eNOS/AMPK dephosphorylation, and VCAM-1-dependent leukocyte adhesion; and MPO enzymatic activity (inhibitable by ceruloplasmin or pharmacological inhibitors) drives oxidative modification of LDL, plaque instability, NET formation, and neuroinflammatory cell death pathways including apoptosis and ferroptosis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"X-ray crystal structure of canine myeloperoxidase at 3 Å resolution revealed a heterotetrameric enzyme (two heavy and two light chains linked by a disulfide bridge), with a covalently bound heme, proximal His336 ligand to heme iron, distal His95 and Arg239 as catalytic residues, a calcium binding site, and covalent linkage to heme tentatively at Glu242.\",\n      \"method\": \"X-ray crystallography (multiple isomorphous replacement, crystallographic refinement)\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure at 3 Å with refinement, foundational structural paper\",\n      \"pmids\": [\"1320128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"X-ray crystal structure of human MPO at 1.8 Å confirmed covalent heme attachment via two ester linkages (Glu242 and Asp94 to modified pyrrole methyl groups on rings A and C) and a sulfonium ion linkage (Met243 to vinyl group on pyrrole ring A). Halide-binding sites were characterized: a native chloride ion near the proximal His336 helix, and a bromide-binding site in the distal heme cavity near His95 that competes with H2O2 and may serve as the halide substrate-binding site in compound I.\",\n      \"method\": \"X-ray crystallography at 1.8 Å (native and bromide-soaked crystals)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional site characterization\",\n      \"pmids\": [\"10766826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Kinetic studies established that thiocyanate is by far the most favored substrate for MPO over chloride and bromide (relative specificity constants Cl:Br:SCN = 1:60:730). At physiological concentrations of thiocyanate and chloride, MPO produces hypothiocyanite alongside HOCl, demonstrating thiocyanate as a major physiological substrate.\",\n      \"method\": \"In vitro enzyme kinetics (H2O2 consumption assay at varied substrate concentrations)\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro kinetic characterization with multiple substrate concentrations\",\n      \"pmids\": [\"9359420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Stopped-flow transient kinetics revealed second-order rate constants for two-electron reduction of MPO compound I by halides and thiocyanate at pH 7: Cl⁻ (2.5×10⁴ M⁻¹s⁻¹), Br⁻ (1.1×10⁶ M⁻¹s⁻¹), I⁻ (7.2×10⁶ M⁻¹s⁻¹), SCN⁻ (9.6×10⁶ M⁻¹s⁻¹). A catalytic residue with pKa ~4.6 must be protonated for optimal halide oxidation. SCN⁻ most effectively shifts MPO from the peroxidatic to the halogenation cycle.\",\n      \"method\": \"Sequential mixing stopped-flow transient kinetics; steady-state spectral and kinetic measurements\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro transient kinetics with rigorous rate constant determinations\",\n      \"pmids\": [\"9922160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MPO catalytically consumes nitric oxide (NO) as a substrate via its compound I and compound II intermediates in a H2O2-dependent manner, independent of chloride. Stopped-flow kinetics showed NO dramatically influences compound II steady-state levels, identifying peroxidases including MPO as a catalytic sink for NO at inflammation sites.\",\n      \"method\": \"Stopped-flow kinetics; steady-state NO consumption assay; in vitro enzyme assay with superoxide-generating system\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with stopped-flow kinetics demonstrating mechanistic interaction\",\n      \"pmids\": [\"11090610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CD36 was identified as the major macrophage scavenger receptor for LDL modified by the MPO-H2O2-NO2⁻ system (NO2-LDL). MPO-dependent LDL modification generates a high-affinity CD36 ligand leading to foam cell formation; lipid oxidation products of phosphatidylcholine serve as the CD36-recognized moieties.\",\n      \"method\": \"Stable transfection of CD36; CD36-specific blocking mAbs; CD36-null macrophages; cholesterol loading and binding assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal approaches including KO cells, blocking antibodies, and receptor reconstitution\",\n      \"pmids\": [\"10772654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MPO localizes in and around vascular endothelial cells following leukocyte degranulation during acute endotoxemia, where it catalytically consumes NO via substrate radicals, impairing endothelium-dependent relaxation. MPO-deficient mice were resistant to this vascular dysfunction, establishing MPO as a vascular NO oxidase modulating NO bioavailability during inflammation.\",\n      \"method\": \"Rodent model of acute endotoxemia; MPO-deficient mice; vascular relaxation assays; direct localization studies\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO model with defined vascular functional phenotype plus localization data, replicated across conditions\",\n      \"pmids\": [\"12089442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"K⁺ flux into the neutrophil phagosome raises ionic strength and releases cationic granule proteins (elastase, cathepsin G) from anionic proteoglycan matrix; MPO-catalyzed halogenation contributes to the phagosomal oxidative environment. Mice deficient in granule proteases (but with intact superoxide/MPO activity) cannot resist staphylococcal/candidal infections, showing proteases are primary bactericidal effectors with MPO providing the oxidative context.\",\n      \"method\": \"Protease-deficient KO mice; infection models; ion flux measurements; morphological analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined infectious phenotype, mechanistic pathway placement\",\n      \"pmids\": [\"11907569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Kinetic modeling of the neutrophil phagosome showed that MPO (present at millimolar concentrations) rapidly converts most superoxide to compound III, that superoxide is essential to recycle compound III and maintain MPO activity, and that MPO efficiently produces HOCl when chloride is adequate. Most HOCl reacts with granule proteins before reaching bacteria, and chloramine products may be the antimicrobial effectors.\",\n      \"method\": \"Kinetic mathematical modeling using known rate constants; estimated phagosomal concentrations\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 kinetic modeling — rigorous but computational without direct experimental validation in phagosome\",\n      \"pmids\": [\"17074761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Upon neutrophil activation, neutrophil elastase (NE) escapes azurophilic granules and translocates to the nucleus where it degrades specific histones, promoting chromatin decondensation for NET formation. MPO then synergizes with NE to drive further chromatin decondensation independently of its enzymatic activity. NE-knockout mice fail to form NETs in a pulmonary Klebsiella pneumoniae model.\",\n      \"method\": \"NE-KO mice; pulmonary infection model; granule fractionation; nuclear translocation imaging; inhibitor studies; NET quantification\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined phenotype plus mechanistic fractionation and imaging, replicated with inhibitors\",\n      \"pmids\": [\"20974816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Neutrophils from completely MPO-deficient donors fail to form NETs, establishing MPO as required for NET formation. Partial MPO deficiency allows NET formation; pharmacological MPO inhibition only delays/reduces NETs. MPO acts cell-autonomously (extracellular MPO products cannot rescue NET formation). NET-dependent killing of Candida albicans is compromised in MPO-deficient neutrophils.\",\n      \"method\": \"Neutrophils from MPO-deficient patients; pharmacological MPO inhibition; NET quantification; Candida killing assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — primary human genetic deficiency, pharmacological inhibition, and functional rescue experiments\",\n      \"pmids\": [\"20974672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Human neutrophil MPO catalyzes biodegradation of single-walled carbon nanotubes via hypochlorite and reactive radical intermediates, both in vitro and in intact neutrophils. Molecular modeling indicated basic amino acids of MPO interact with carboxyls on nanotubes to position them near the catalytic site. Biodegraded nanotubes do not induce pulmonary inflammation in mice.\",\n      \"method\": \"In vitro MPO enzymatic assay; cell-based degradation in neutrophils and macrophages; molecular modeling; mouse aspiration model\",\n      \"journal\": \"Nature nanotechnology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzymatic reconstitution, cell studies, molecular modeling, and in vivo validation\",\n      \"pmids\": [\"20364135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MPO bound to NETs retains enzymatic peroxidase activity (~30% of total cellular MPO released with majority NET-bound). NET-associated MPO mediates H2O2-dependent killing of Staphylococcus aureus, demonstrating that MPO on NETs can contribute to extracellular antimicrobial activity.\",\n      \"method\": \"PMA-stimulated NET formation; peroxidase activity assay on NETs; MPO inhibitor; S. aureus killing assay with DNase-released NETs\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct enzyme activity measurement on NETs plus functional bacterial killing assay\",\n      \"pmids\": [\"22131345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Requirements for NADPH oxidase and MPO in NET formation are stimulus-dependent: PMA and bacterial stimuli require NADPH oxidase; MPO is required for efficient PMA-induced NETs but dispensable for bacterium-induced NETs. Ionomycin (calcium ionophore) induces NETs independently of both NADPH oxidase and MPO.\",\n      \"method\": \"NADPH oxidase and MPO inhibitors; cells from MPO-deficient donor; multiple stimuli (PMA, bacteria, ionomycin); NET quantification\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetic deficiency plus pharmacological inhibitors across multiple stimuli\",\n      \"pmids\": [\"22802447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MPO forms a membrane-associated complex in azurophilic granules with NE that prevents NE release. ROS triggers MPO-dependent dissociation of NE from this complex into the cytosol and activates NE proteolytic activity. In the cytosol, NE binds and degrades F-actin to arrest actin dynamics before translocating to the nucleus during NETosis. This complex functions as an oxidative signaling scaffold.\",\n      \"method\": \"Biochemical fractionation; co-immunoprecipitation; actin dynamics assays; MPO inhibitors; NE activity assays; NET formation imaging\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical methods identifying complex, mechanism, and functional consequence\",\n      \"pmids\": [\"25066128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Different NETosis stimuli engage distinct signaling pathways: PMA, C. albicans, and Group B Streptococcus use a PKC/ROS/MPO/NE-dependent pathway, whereas calcium ionophores (A23187, nigericin) require an alternative pathway independent of MPO and NADPH oxidase. All NET types are proteolytically active and kill bacteria.\",\n      \"method\": \"Pharmacological inhibitors (PKC, calcium, ROS, MPO, NE); neutrophils from chronic granulomatous disease and MPO-deficient patients; multiple stimuli; bacterial killing assay\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetic deficiency models plus pharmacological dissection across multiple stimuli\",\n      \"pmids\": [\"28574339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Enzymatically active MPO and its oxidation products (chlorotyrosine) are present in human brain neurons (hippocampal granule and pyramidal neurons) and activated microglia. MPO expression is increased in Alzheimer's disease brain tissue particularly in neurons and amyloid plaques. Several neuronal cell lines express MPO mRNA and protein, revealing unexpected neuronal expression of MPO.\",\n      \"method\": \"Immunohistochemistry; enzymatic activity assay; mass spectrometric detection of chlorotyrosine; RT-PCR; neuronal cell line analysis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods (IHC, enzymatic activity, MS oxidation products, mRNA) in human tissue and cell lines\",\n      \"pmids\": [\"15255951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Ceruloplasmin physically binds MPO and inhibits its peroxidase activity in a concentration-dependent manner. This interaction was demonstrated by MPO-affinity chromatography retaining ceruloplasmin from plasma, selective binding to MPO-coated plates (blockable by soluble MPO), and reciprocal binding of MPO to ceruloplasmin-coated plates (blockable by ceruloplasmin). C3 also binds MPO but does not inhibit its peroxidase activity.\",\n      \"method\": \"MPO-affinity chromatography; N-terminal amino acid sequencing; ELISA binding assays; peroxidase activity inhibition assay\",\n      \"journal\": \"Clinical and experimental immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding assays plus enzymatic inhibition with purified proteins\",\n      \"pmids\": [\"9097926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Expression of MPO on the neutrophil surface is required for neutrophil activation by anti-MPO antibodies (ANCA). MPO-deficient neutrophils (completely and partially) showed no superoxide anion production in response to monoclonal anti-MPO or MPO-ANCA IgG, despite normal responses to other stimuli. Mutations causing deficiency were characterized at the molecular level.\",\n      \"method\": \"Neutrophils from MPO-deficient donors; superoxide anion production assay; immunocytochemistry; immunoblotting; mutation sequencing\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetic deficiency with functional activation assays and molecular characterization of mutations\",\n      \"pmids\": [\"12773517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MPO activates µ-calpain (but not m-calpain) in endothelial cells through denitrosylation of the µ-calpain C-terminus domain. Activated µ-calpain upregulates PP2A expression, which dephosphorylates AMPK (Thr172) and eNOS (Ser1177), leading to increased VCAM-1 and leukocyte adhesion. µ-Calpain-deficient mice showed reduced leukocyte adhesion in response to MPO, placing calpain as a novel downstream signaling target in MPO-induced endothelial dysfunction.\",\n      \"method\": \"Endothelial cell stimulation with MPO; calpain isoform-specific assays; pharmacological calpain inhibition; PP2A/AMPK/eNOS phosphorylation western blots; µ-calpain-deficient mice; leukocyte adhesion assay\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO mice plus pharmacological inhibition with defined molecular pathway (denitrosylation → calpain → PP2A → AMPK/eNOS)\",\n      \"pmids\": [\"29507101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"T47D breast cancer cells stably transfected with MPO replicate all post-ER processing steps for mature MPO heterotetramer formation, including proteolytic pro-domain removal, heavy/light chain separation, and inter-molecular disulfide bond formation. MPO traffics to lysosomes. Cys319 (which forms the inter-molecular disulfide bond) is also required for events preceding disulfide bonding: its mutation alters glycosylation, catalytic activity, and blocks entry into the endocytic pathway where proteolytic processing occurs.\",\n      \"method\": \"Stable transfection of MPO into T47D cells; site-directed mutagenesis of Cys319; immunofluorescence microscopy; glycosylation analysis; catalytic activity assay; endocytic pathway analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis combined with biochemical processing assays and microscopy in a novel cell model\",\n      \"pmids\": [\"26890638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The human MPO promoter contains seven discrete nuclear protein binding sites (DP1–DP7) within the proximal 600 bp of 5'-flanking DNA, identified by DNase I footprinting and gel shift analysis. These sites show tissue-specific and maturation-specific differences in nuclear protein binding. Mutation of DP7 stimulates MPO promoter activity, while mutation of any of DP1–DP6 reduces activity, establishing them as positive cis-regulatory elements.\",\n      \"method\": \"DNase I footprinting; gel shift assays; promoter-reporter transfection with site-directed mutations\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional mutagenesis combined with protein binding assays identifies specific cis-elements\",\n      \"pmids\": [\"8683986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"A myeloid-lineage-specific enhancer for the murine MPO gene was identified 3.2–3.4 kb upstream, marked by a DNase I hypersensitive site. A 301 bp fragment encompassing this site has strong enhancer activity in MPO-expressing myeloid cells (WEHI 3BD+) but is inactive in lymphoid cells, requiring the complete 301 bp fragment for maximal activity.\",\n      \"method\": \"DNase I hypersensitivity mapping; transient transfection reporter assay in myeloid vs. lymphoid cell lines\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional enhancer activity demonstrated in cell-type-specific manner with deletion analysis\",\n      \"pmids\": [\"8182931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The human MPO gene is transcribed in vivo primarily from the P1 promoter (~bp +1), with two additional non-canonical transcription initiation sites at P2 (~bp -310) and P3 (~bp -920). Transcription from P1 produces full-length coding transcripts and shows the expected downregulation upon myeloid differentiation. P2 and P3 transcripts do not downregulate upon TPA-induced macrophage differentiation, are non-tissue-specific, frequently terminate prematurely, and do not contribute to physiologic MPO expression.\",\n      \"method\": \"Primer extension; RT-PCR; Northern blot analysis of myeloid cell lines before and after differentiation induction\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple primer extension and RT-PCR experiments with differentiation induction defining promoter usage in vivo\",\n      \"pmids\": [\"12040446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MPO inhibition with the suicide inhibitor AZM198 stabilizes pre-existing unstable atherosclerotic plaque in the Tandem Stenosis mouse model, increasing fibrous cap thickness indicative of plaque stabilization, without altering cellular content (Ly6B.2+ or CD68+ cells) or MPO protein levels. In vivo molecular MRI showed elevated arterial MPO activity precedes unstable plaque formation.\",\n      \"method\": \"Tandem Stenosis mouse model; pharmacological MPO inhibition (AZM198); in vivo molecular MRI of MPO activity; histological analysis\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo pharmacological intervention with imaging-confirmed target engagement and defined structural phenotype\",\n      \"pmids\": [\"36375379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A homozygous missense mutation c.1769G>T (p.Arg590Leu) in MPO abolishes heme binding (structural analysis) and completely eliminates myeloperoxidase enzymatic activity in vitro. The mutant protein is stably expressed in culture but shows markedly reduced expression in patient skin in vivo, and is associated with generalized pustular psoriasis (GPP). Reduced NETosis (sparse NET formation in pustules) was observed in patient skin.\",\n      \"method\": \"Structural analysis (in silico heme binding prediction); in vitro myeloperoxidase activity assay in cultured cells; immunohistochemistry (anti-MPO and anti-citrullinated histone H3)\",\n      \"journal\": \"The Journal of dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional enzyme assay, structural prediction, and in vivo histology converging on complete loss-of-function\",\n      \"pmids\": [\"36585391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MPO-oxidized LDLs (Mox-LDLs) drive macrophage foam cell formation and increase intracellular ROS, but also stimulate endothelial cells to produce resolvin D1 (RvD1), a specialized pro-resolving mediator that reduces neutrophil/monocyte recruitment and promotes efferocytosis. Mox-LDLs thus exert a dual effect on inflammation through MPO-dependent LDL oxidation.\",\n      \"method\": \"In vitro cell-based assays with Mox-LDLs and macrophages/endothelial cells; RvD1 measurement\",\n      \"journal\": \"Antioxidants\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — cell-based assays with defined outcomes but no genetic validation or in vivo model reported in this review\",\n      \"pmids\": [\"35624738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MPO inhibition with verdiperstat attenuates LPS-induced acute lung injury in rats via the MPO/µ-calpain/β-catenin signaling pathway: MPO inhibition reduces µ-calpain activation, decreases nuclear β-catenin translocation, and restores VE-cadherin and claudin-5 levels, strengthening endothelial barrier function.\",\n      \"method\": \"LPS-induced two-hit rat ALI model; verdiperstat (MPO inhibitor) treatment; western blotting of µ-calpain cleavage, β-catenin localization, VE-cadherin, claudin-5; in vitro HPMEC model\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition in vivo and in vitro with defined molecular pathway readouts\",\n      \"pmids\": [\"35461824\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MPO is a heme-containing heterotetrameric peroxidase stored in neutrophil azurophilic granules whose catalytic core (with proximal His336, distal His95/Arg239, and covalent heme linkages at Glu242, Asp94, and Met243) oxidizes halides and thiocyanate (preferred order SCN⁻ >> I⁻ > Br⁻ >> Cl⁻) to hypohalous acids using H2O2; it also catalytically consumes nitric oxide, modulating vascular NO bioavailability. During NETosis, MPO forms a membrane complex with neutrophil elastase in azurophilic granules; ROS triggers MPO-dependent dissociation and activation of elastase, which degrades F-actin and translocates to the nucleus to decondense chromatin, with MPO then synergizing non-enzymatically to complete chromatin decondensation, making MPO essential for PMA-induced (but not ionophore-induced) NET formation. MPO also activates µ-calpain in endothelial cells via denitrosylation, suppressing eNOS phosphorylation through PP2A to promote vascular inflammation, and MPO-oxidized LDL is recognized by scavenger receptor CD36 to drive foam cell formation; MPO expression is controlled by seven cis-regulatory elements in its proximal promoter and a myeloid-specific upstream enhancer, with transcription occurring primarily from the P1 promoter during early myeloid differentiation and being downregulated upon terminal differentiation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MPO encodes myeloperoxidase, a heme-containing peroxidase stored in neutrophil and monocyte azurophilic granules that catalyzes the production of hypochlorous acid (HOCl) from hydrogen peroxide and chloride, driving antimicrobial defense, neutrophil extracellular trap (NET) formation, and oxidative tissue injury [PMID:26026247, PMID:36585391]. Transcription is governed by a primary P1 promoter containing at least seven cis-regulatory elements (DP1–DP7) and a distal myeloid-lineage-specific enhancer, with expression restricted to early myeloid differentiation stages (M1–M4 AML) and downregulated during terminal differentiation [PMID:8683986, PMID:8182931, PMID:12040446, PMID:2165203]. Biosynthetic maturation of proMPO requires Cys319 for proper glycosylation and entry into the endocytic pathway, where proteolytic processing and disulfide-linked heterotetramer assembly occur in lysosomal compartments [PMID:26890638]. Beyond its granule-based oxidant role, secreted MPO activates endothelial µ-calpain through denitrosylation, leading to PP2A-mediated dephosphorylation of AMPK and eNOS, VCAM-1 upregulation, and enhanced leukocyte adhesion, while its enzymatic activity drives LDL oxidation and atherosclerotic plaque instability [PMID:29507101, PMID:36375379].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Establishing that MPO expression is developmentally regulated during myelopoiesis answered the question of when and where MPO is transcribed: four mRNA species are transiently induced then silenced during differentiation, with expression restricted to early myeloid (M1–M4) but not monocytic (M5) or lymphoid leukemias.\",\n      \"evidence\": \"Northern blot, primer extension, and S1 nuclease protection in HL-60 cells and primary AML samples\",\n      \"pmids\": [\"2165203\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of transcription factors driving the stage-specific shutoff was unknown\", \"Mechanism of alternative transcript generation was not resolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Discovery of a distal myeloid-specific enhancer ~3.2–3.4 kb upstream of the MPO gene established how lineage restriction of MPO transcription is enforced at the chromatin level.\",\n      \"evidence\": \"DNase I hypersensitive-site mapping and reporter assays in granulocytic vs lymphoid cells (mouse MPO locus)\",\n      \"pmids\": [\"8182931\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-acting factors binding this enhancer were not identified\", \"Human enhancer equivalence assumed but not directly tested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Functional dissection of the proximal promoter identified seven discrete cis-elements (DP1–DP7) that collectively tune MPO transcription, resolving how the proximal regulatory region integrates positive and negative signals in a tissue-specific manner.\",\n      \"evidence\": \"DNase I footprinting, gel shift, and site-directed mutagenesis coupled to reporter assays in myeloid cell lines\",\n      \"pmids\": [\"8683986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the nuclear proteins binding DP1–DP7 was not determined\", \"In vivo chromatin occupancy not tested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstration that ceruloplasmin physically binds MPO and inhibits its peroxidase activity identified an endogenous regulatory mechanism that limits HOCl-mediated tissue damage at sites of inflammation.\",\n      \"evidence\": \"Affinity chromatography, reciprocal plate binding assays, and competitive inhibition of peroxidase activity in vitro\",\n      \"pmids\": [\"9097926\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of ceruloplasmin–MPO interaction not demonstrated\", \"Stoichiometry and binding interface not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapping three transcription start sites (P1, P2, P3) clarified that the P1 promoter drives the predominant physiological MPO transcripts and is the site of differentiation-dependent downregulation, while P2/P3 yield non-tissue-specific, often prematurely terminated transcripts.\",\n      \"evidence\": \"Primer extension, RT-PCR, Northern blot, and transfection studies in myeloid cell lines\",\n      \"pmids\": [\"12040446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional protein products from P2/P3 transcripts not assessed\", \"Epigenetic silencing mechanism of P1 during differentiation not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Using neutrophils from naturally MPO-deficient individuals proved that surface-expressed MPO is required for ANCA-mediated neutrophil activation, establishing MPO as the direct antigen target in MPO-ANCA vasculitis pathogenesis.\",\n      \"evidence\": \"Superoxide production assay in MPO-deficient human neutrophils stimulated with anti-MPO ANCA IgG; gene mutation identification by sequencing\",\n      \"pmids\": [\"12773517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which MPO reaches the cell surface was not elucidated\", \"Whether partial MPO deficiency modifies ANCA response was untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Pharmacological inhibition showed that MPO enzymatic activity is required for NET formation in response to microbial stimuli, placing MPO upstream of chromatin decondensation in NETosis alongside neutrophil elastase and NADPH oxidase.\",\n      \"evidence\": \"MPO inhibitor treatment with NET quantification by co-localization of extracellular DNA with MPO/histone/NE in human and bovine neutrophils challenged with C. parvum\",\n      \"pmids\": [\"26026247\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Catalytic vs non-catalytic contribution of MPO to chromatin decondensation not separated\", \"Generalizability across different NET-inducing stimuli not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Site-directed mutagenesis of Cys319 revealed that this residue is essential for proper glycosylation, catalytic activity, and entry of proMPO into the endocytic pathway, resolving a key step in the multi-stage biosynthetic maturation that culminates in disulfide-linked heterotetramer formation in lysosomes.\",\n      \"evidence\": \"Stable expression of wild-type and C319 mutant MPO in T47D cells with immunofluorescence, lysosomal trafficking, and enzymatic activity analysis\",\n      \"pmids\": [\"26890638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of Cys319 role in glycosylation not determined\", \"Processing in actual myeloid progenitors not confirmed for mutant\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Discovery that secreted MPO activates endothelial µ-calpain via denitrosylation, triggering PP2A-dependent dephosphorylation of AMPK/eNOS and VCAM-1 upregulation, established a non-oxidant signaling axis through which extracellular MPO promotes leukocyte adhesion and vascular dysfunction.\",\n      \"evidence\": \"Endothelial cell stimulation with MPO, pharmacological calpain inhibition, µ-calpain-knockout mouse model, phosphorylation and adhesion assays\",\n      \"pmids\": [\"29507101\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this pathway requires MPO catalytic activity or protein interaction was not fully resolved\", \"Receptor or uptake mechanism for MPO on endothelial cells not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"In vivo MPO inhibition with AZM198 stabilized pre-existing unstable atherosclerotic plaques by increasing fibrous cap thickness without altering inflammatory cell content, proving that MPO enzymatic activity — not merely protein presence — drives plaque instability.\",\n      \"evidence\": \"Interventional pharmacological MPO inhibition in Tandem Stenosis mouse model with molecular MRI of MPO activity and histological analysis\",\n      \"pmids\": [\"36375379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific MPO-derived oxidant (HOCl vs tyrosyl radicals) responsible for matrix degradation not distinguished\", \"Translatability to human atherosclerosis uncertain\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A homozygous R590L MPO mutation that abolishes heme binding and enzymatic activity while permitting protein expression, associated with generalized pustular psoriasis and sparse NETs in patient skin, established a human genetic link between MPO loss-of-function and inflammatory skin disease.\",\n      \"evidence\": \"Structural prediction of mutant MPO, in vitro activity assay, immunohistochemistry for MPO and citrullinated histone H3 in patient tissue\",\n      \"pmids\": [\"36585391\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal relationship between MPO deficiency and pustular psoriasis not established beyond association in a single kindred\", \"Contribution of impaired NETs versus other MPO functions to skin phenotype not dissected\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The MPO/µ-calpain axis was extended to lung injury when verdiperstat inhibited µ-calpain/β-catenin signaling and restored endothelial junctional proteins, broadening the pathological relevance of extracellular MPO beyond the vasculature.\",\n      \"evidence\": \"In vivo LPS two-hit rat ALI model and in vitro pulmonary endothelial cells with pharmacological MPO inhibition and Western blot pathway analysis\",\n      \"pmids\": [\"35461824\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genetic confirmation of MPO dependence in ALI not provided\", \"β-catenin as direct calpain substrate in this context not validated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"MPO was placed upstream of both apoptosis (Bax/Bcl-2/caspase-3) and ferroptosis (GPX4/NQO1 suppression) in ALS motor neurons via HOCl production, suggesting a dual cell-death mechanism for MPO-driven neuroinflammatory damage.\",\n      \"evidence\": \"HOCl fluorescent probe, SOD1G93A cell and mouse models, apoptosis/ferroptosis assays, pharmacological MPO inhibition with rotarod behavioral test\",\n      \"pmids\": [\"35178161\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MPO is expressed by motor neurons themselves or infiltrating myeloid cells was not resolved\", \"Ferroptosis link relies on GPX4 decrease without lipid peroxide rescue experiments\", \"Single-lab finding not independently replicated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of trans-acting factors at DP1–DP7, the mechanism by which MPO reaches the neutrophil surface, structural details of the ceruloplasmin–MPO inhibitory interface, and whether the µ-calpain denitrosylation axis requires MPO catalytic activity or a separate protein–protein interaction.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of the mature MPO heterotetramer in complex with physiological inhibitors\", \"Endothelial MPO receptor/uptake pathway unidentified\", \"Relative contributions of HOCl vs other MPO-derived oxidants to individual disease phenotypes remain unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 9, 10, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [6, 11]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [7, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 9, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 10, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CP\",\n      \"CAPN1\",\n      \"IGF2BP2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Myeloperoxidase (MPO) is a heme-containing heterotetrameric peroxidase stored in neutrophil azurophilic granules that generates hypohalous acids (HOCl, HOBr, HOSCN) from halides and thiocyanate using H₂O₂, with thiocyanate as the kinetically preferred substrate (SCN⁻ >> I⁻ > Br⁻ >> Cl⁻), and also catalytically consumes nitric oxide to modulate vascular NO bioavailability [PMID:9359420, PMID:9922160, PMID:11090610, PMID:12089442]. During NETosis, MPO forms a granule-membrane complex with neutrophil elastase (NE); ROS-triggered dissociation releases and activates NE, which degrades F-actin and translocates to the nucleus to decondense chromatin, after which MPO synergizes non-enzymatically to complete chromatin decondensation—making MPO essential for PMA-induced but dispensable for ionophore-induced NET formation [PMID:20974816, PMID:20974672, PMID:25066128, PMID:28574339]. MPO also drives vascular inflammation by activating endothelial µ-calpain via denitrosylation, suppressing eNOS phosphorylation through PP2A, and by generating oxidized LDL species recognized by the scavenger receptor CD36 to promote foam cell formation and atherosclerotic plaque instability [PMID:29507101, PMID:10772654, PMID:36375379]. A homozygous loss-of-function MPO mutation (p.Arg590Leu) that abolishes heme binding is associated with generalized pustular psoriasis and defective NETosis [PMID:36585391].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Determination of the first MPO crystal structure revealed the heterotetrameric architecture, covalent heme attachment, and catalytic residues (proximal His336, distal His95/Arg239), establishing the structural framework for understanding halide oxidation.\",\n      \"evidence\": \"X-ray crystallography at 3 Å of canine MPO with multiple isomorphous replacement\",\n      \"pmids\": [\"1320128\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Covalent heme linkages only tentatively assigned at this resolution\", \"Human MPO structure not yet determined\", \"No halide-binding site directly visualized\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Identification of a myeloid-specific upstream enhancer and proximal promoter elements established the transcriptional regulatory framework for lineage-restricted MPO expression.\",\n      \"evidence\": \"DNase I hypersensitivity mapping and reporter assays in myeloid vs. lymphoid cell lines; DNase I footprinting and site-directed mutagenesis of promoter elements\",\n      \"pmids\": [\"8182931\", \"8683986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-acting factors binding DP1–DP7 elements not identified\", \"Chromatin context in primary myeloid progenitors not assessed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Kinetic characterization revealed thiocyanate as MPO's most favored physiological substrate over chloride and bromide, reframing MPO as a hypothiocyanite-producing enzyme alongside its HOCl-generating role, while ceruloplasmin was identified as a physiological inhibitor of MPO activity.\",\n      \"evidence\": \"In vitro enzyme kinetics with varied substrate concentrations; MPO-affinity chromatography and reciprocal binding assays with purified ceruloplasmin\",\n      \"pmids\": [\"9359420\", \"9097926\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relative contributions of HOSCN vs. HOCl not quantified\", \"Structural basis of ceruloplasmin–MPO interaction unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Stopped-flow transient kinetics defined absolute rate constants for compound I reduction by each halide and SCN⁻, revealing a catalytic residue with pKa ~4.6 required for halide oxidation and establishing that SCN⁻ most effectively shifts MPO from the peroxidatic to the halogenation cycle.\",\n      \"evidence\": \"Sequential mixing stopped-flow spectroscopy with compound I/II intermediates\",\n      \"pmids\": [\"9922160\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the pKa ~4.6 residue not assigned\", \"Phagosomal pH dynamics not integrated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"High-resolution human MPO structure resolved the three covalent heme linkages (Glu242, Asp94 ester bonds; Met243 sulfonium) and identified the distal halide-binding site, while parallel work established MPO as a catalytic NO sink and showed MPO-oxidized LDL drives CD36-dependent foam cell formation.\",\n      \"evidence\": \"1.8 Å X-ray crystallography of native and bromide-soaked crystals; stopped-flow NO consumption kinetics; CD36-transfected cells, CD36-null macrophages, and blocking antibodies\",\n      \"pmids\": [\"10766826\", \"11090610\", \"10772654\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo NO consumption kinetics at inflammatory sites not measured\", \"Structural basis of MPO–LDL interaction unresolved\", \"Compound I–halide ternary complex not crystallized\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"MPO-deficient mice demonstrated that MPO catalytically consumes NO in vivo to impair endothelium-dependent vasodilation during inflammation, while granule protease-deficient mice showed that neutrophil proteases (not MPO-derived oxidants alone) are the primary bactericidal effectors, and promoter studies defined P1 as the physiologically relevant transcription start site.\",\n      \"evidence\": \"MPO-KO and protease-KO mouse infection/vascular relaxation models; primer extension and RT-PCR in differentiating myeloid cells\",\n      \"pmids\": [\"12089442\", \"11907569\", \"12040446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of HOCl vs. chloramines to microbial killing in vivo unresolved\", \"Mechanism of MPO subendothelial transcytosis not determined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Surface-expressed MPO was shown to be required for anti-MPO ANCA-mediated neutrophil activation, linking MPO to ANCA-associated vasculitis pathogenesis.\",\n      \"evidence\": \"Superoxide production assays in neutrophils from MPO-deficient donors stimulated with anti-MPO antibodies\",\n      \"pmids\": [\"12773517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of MPO surface translocation not defined\", \"Whether surface MPO retains enzymatic activity during ANCA engagement unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"MPO was established as essential for PMA-induced NETosis through a non-enzymatic synergy with neutrophil elastase in chromatin decondensation, with NE requiring prior MPO-dependent release from azurophilic granules and nuclear translocation to degrade histones.\",\n      \"evidence\": \"NE-KO mice with pulmonary infection; neutrophils from completely MPO-deficient human donors; granule fractionation and nuclear translocation imaging; NET quantification and Candida killing assays\",\n      \"pmids\": [\"20974816\", \"20974672\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of MPO's non-enzymatic chromatin decondensation activity unknown\", \"Whether MPO directly binds chromatin or histones not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that MPO and NE form a membrane-associated complex in azurophilic granules that acts as a ROS-sensing scaffold resolved how oxidative signals trigger NE release: ROS dissociates NE from MPO, enabling NE to degrade F-actin and halt actin dynamics before nuclear translocation.\",\n      \"evidence\": \"Co-immunoprecipitation; biochemical fractionation; actin dynamics assays; MPO inhibitors; NE activity assays\",\n      \"pmids\": [\"25066128\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural basis of the MPO–NE complex not determined\", \"ROS species responsible for complex dissociation not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Reconstitution of MPO biosynthesis in a non-myeloid cell line demonstrated that Cys319 is required not only for the inter-molecular disulfide bond forming the heterotetramer but also for correct glycosylation and entry into the endocytic processing pathway.\",\n      \"evidence\": \"Stable transfection of MPO into T47D cells; Cys319 site-directed mutagenesis; glycosylation analysis and endocytic pathway microscopy\",\n      \"pmids\": [\"26890638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chaperones and proteases mediating pro-domain removal not identified\", \"Structural basis of Cys319-dependent glycosylation control unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Systematic dissection of NETosis stimuli confirmed two distinct pathways: a PKC/ROS/MPO/NE-dependent pathway (PMA, Candida, Streptococcus) and an MPO/NADPH oxidase-independent calcium pathway (ionophores), clarifying the stimulus-dependent requirement for MPO.\",\n      \"evidence\": \"Pharmacological inhibitor panel plus neutrophils from CGD and MPO-deficient patients across multiple stimuli\",\n      \"pmids\": [\"28574339\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Calcium-dependent NETosis effectors downstream of ionophore not identified\", \"Whether mixed pathways operate simultaneously in vivo unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"MPO was shown to activate endothelial µ-calpain (but not m-calpain) through denitrosylation, establishing a signaling cascade (µ-calpain → PP2A → AMPK/eNOS dephosphorylation → VCAM-1 upregulation) that explains how MPO promotes vascular inflammation beyond oxidant generation.\",\n      \"evidence\": \"Endothelial cell stimulation; calpain isoform-specific assays; µ-calpain-deficient mice; phosphorylation western blots; leukocyte adhesion assay\",\n      \"pmids\": [\"29507101\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct denitrosylation of µ-calpain not demonstrated biochemically with purified proteins\", \"Whether this pathway operates in human vasculature in vivo not confirmed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Multiple 2022 studies consolidated MPO's pathological roles: pharmacological MPO inhibition stabilized atherosclerotic plaque in vivo, a homozygous loss-of-function mutation (Arg590Leu) abolishing heme binding was linked to generalized pustular psoriasis with defective NETosis, and MPO inhibition attenuated acute lung injury via the µ-calpain/β-catenin pathway.\",\n      \"evidence\": \"Tandem Stenosis mouse model with AZM198 and molecular MRI; patient mutation analysis with structural prediction and in vitro activity assay; rat ALI model with verdiperstat and junction protein analysis\",\n      \"pmids\": [\"36375379\", \"36585391\", \"35461824\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical efficacy of MPO inhibitors in human cardiovascular or pulmonary disease not demonstrated\", \"Mechanistic link between MPO deficiency and pustular psoriasis pathogenesis beyond NETosis not explored\", \"β-catenin signaling downstream of µ-calpain not fully characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the non-enzymatic MPO–chromatin interaction during NETosis, the identity of the ROS species dissociating the MPO–NE granule complex, the in vivo relative contributions of HOCl vs. HOSCN vs. chloramines to antimicrobial defense, and whether therapeutic MPO inhibition translates to clinical benefit in cardiovascular and inflammatory diseases.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of MPO bound to chromatin or NE exists\", \"In vivo pharmacokinetics of MPO-generated oxidants within the phagosome remain modeled rather than measured\", \"Clinical trials of MPO inhibitors in atherosclerosis or ANCA vasculitis are ongoing but lack definitive outcomes\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 8, 11, 12]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [14, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [7, 14]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [6, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 9, 10, 13, 14, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 6, 24, 25]}\n    ],\n    \"complexes\": [\n      \"MPO-NE azurophilic granule membrane complex\"\n    ],\n    \"partners\": [\n      \"ELANE\",\n      \"CD36\",\n      \"CAPN1\",\n      \"CP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}